

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013135 A1

(51) International Patent Classification⁷: **C07D 417/14**,
401/14, 407/14, 471/04, A61K 31/4439, 31/444, A61P
1/16

Recherches, Z A de Courtaboeuf, 25, avenue de Quebec,
F-91940 Les Ulis (FR).

(21) International Application Number:
PCT/EP2003/008496

(74) Agent: SEWELL, Richard, Charles; GlaxoSmithKline,
Corporate Intellectual Property CN925.1, 980 Great West
Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 29 July 2003 (29.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0217751.7 31 July 2002 (31.07.2002) GB
0314698.2 24 June 2003 (24.06.2003) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P O Box 7929, Philadelphia,
PA 19101 (US).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): DODIC, Ner-
ina [FR/FR]; Laboratoire GlaxoSmithKline, Centre de
Recherches, Z A de Courtaboeuf, 25, avenue de Que-
bec, F-91940 Les Ulis (FR). GELLIBERT, Francoise,
Jeanne [FR/FR]; Laboratoire GlaxoSmithKline, Centre de

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS

(57) Abstract: This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, ("TGF")- β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

WO 2004/013135 A1

2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS


This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, ("TGF")- β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

10 TGF- β 1 is the prototypic member of a family of cytokines including the TGF- β s, activins, inhibins, bone morphogenetic proteins and Müllerian-inhibiting substance, that signal through a family of single transmembrane serine/threonine kinase receptors. These receptors can be divided into two classes, the type I or activin like kinase (ALK) receptors and type II receptors. The ALK receptors are distinguished from the type II receptors in that the ALK receptors (a) lack the serine/threonine rich intracellular tail, (b) possess serine/threonine kinase domains that are very homologous between type I receptors, and (c) share a common sequence motif called the GS domain, consisting of a region rich in glycine and serine residues. The GS domain is at the amino terminal end of the intracellular kinase domain and is critical for activation by the type II receptor. Several studies have shown that TGF- β signalling requires both the ALK and type II receptors. Specifically, the type II receptor phosphorylates the GS domain of the type I receptor for TGF- β , ALK5, in the presence of TGF- β . The ALK5, in turn, phosphorylates the cytoplasmic proteins smad2 and smad3 at two carboxy terminal serines. The phosphorylated smad proteins translocate into the nucleus and activate genes that contribute to the production of extracellular matrix. Therefore, preferred compounds of this invention are selective in that they inhibit the type I receptor and thus matrix production.

Surprisingly, it has now been discovered that a class of novel 2-phenylpyridin-4-yl heterocyclyl derivatives function as potent and selective non-peptide inhibitors of ALK5 kinase.

According to a first aspect, the invention provides a compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:

2



(I)

wherein

A is furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazole, isoxazole, oxazoline, oxazolidine, thiazole, isothiazole, thiadiazole, benzofuran, indole, isoindole, indazole, imidazopyridine, quinazoline, quinoline, isoquinoline, pyrazole or triazole;

X is N or CH;

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro C₁₋₆alkyl, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -CO(CH₂)_nNR⁵R⁶, -SO₂R⁷, -SO₂NR⁵R⁶, -NR⁵SO₂R⁷, -NR⁵COR⁷, -O(CH₂)_nCONR⁵R⁶, -NR⁵CO(CH₂)_nNR⁵R⁶ or -C(O)R⁷;

R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, phenyl, C₁₋₆alkyl or -NR⁵R⁶;

where

R⁵ and R⁶ are independently selected from hydrogen; Het; C₃₋₆cycloalkyl optionally substituted by C₁₋₆alkyl; or by C₁₋₆alkyl optionally substituted by Het, alkoxy, cyano or -NR^aR^b (where R^a and R^b which may be the same or different are hydrogen or C₁₋₆alkyl, or R^a and R^b together with the nitrogen atom to which they are attached may form a 4,5 or 6-membered saturated ring); or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, -CF₃, hydroxy, -OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;

R⁷ is selected from hydrogen and C₁₋₆alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C₁₋₆alkyl; and

n is 1-4;

with the provisos that:

a) when A is thiazole (wherein the thiazole sulfur is on the same side as the 4-pyridyl moiety); X is N; R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkyl or perfluoroC₁₋₆alkoxy; R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl; and R³ is hydrogen or halo; then R⁴ is not NH₂; and

b) when X is N, A is pyrazole (where the ring containing X is attached to the pyrazole ring at carbon atom next to a pyrazole ring nitrogen) and R² is hydrogen then R³ is not hydrogen.

The term "C₁₋₆alkyl" as used herein, whether on its own or as part of a group, refers to a straight or branched chain saturated aliphatic hydrocarbon radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl and hexyl.

The term "alkenyl" as a group or part of a group refers to a straight or branched chain mono- or poly-unsaturated aliphatic hydrocarbon radical containing the specified number(s) of carbon atoms. References to "alkenyl" groups include groups which may be in the E- or Z-form or mixtures thereof.

The term "alkoxy" as a group or part of a group refers to an alkyl ether radical, wherein the term "alkyl" is defined above. Such alkoxy groups in particular include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy and tert-butoxy.

The term "perfluoroalkyl" as used herein includes compounds such as trifluoromethyl.

The term "perfluoroalkoxy" as used herein includes compounds such as trifluoromethoxy.

The terms "halo" or "halogen" are used interchangeably herein to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.

The term "heterocyclyl" as used herein includes cyclic groups containing 5 to 7 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen, oxygen and sulfur,

and may be saturated, unsaturated or aromatic. Examples of heterocyclyl groups are furyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, sulfolanyl, tetrazolyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl, diazepinyl and thiazolinyl. In addition, the term heterocyclyl includes fused heterocyclyl groups, for example benzimidazolyl, benzoxazolyl, imidazopyridinyl, benzoxazinyl, benzothiazinyl, oxazolopyridinyl, benzofuranyl, quinolinyl, quinazolinyl, quinoxalinyl, dihydroquinazolinyl, benzothiazolyl, phthalimido, benzofuranyl, benzodiazepinyl, indolyl and isoindolyl.

Preferably, A is furan, thiophene, pyrrole, imidazole, pyridine, pyrimidine, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, imidazopyridine, pyrazole or triazole; each of which is optionally substituted by one or more of the substituents R⁴.

More preferably, A is triazole, imidazopyridine, thiazole, imidazole or pyrazole; each of which is optionally substituted by one or more of the substituents R⁴.

Still more preferably A is imidazopyridine, thiazole or imidazole; each of which is optionally substituted by one R⁴ substituent.

Yet more preferably A is imidazole optionally substituted by one R⁴ substituent.

Preferably X is N.

Preferably R¹ is C₁₋₆alkyl, C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -SO₂R⁷, -NR⁵SO₂R⁷, -NR⁵COR⁷, -O(CH₂)_nCONR⁵R⁶, -NR⁵CO(CH₂)_nNR⁵R⁶ or -C(O)R⁷.

More preferably R¹ is C₁₋₆alkoxy, halo, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -SO₂R⁷ or -O(CH₂)_nCONR⁵R⁶.

Preferably R² is hydrogen, C₁₋₆alkyl or fluoro. More preferably R² is hydrogen or methyl. More preferably still, R² is methyl.

Preferably R³ is hydrogen.

Preferably, when X is N, R² is methyl. More preferably when X is N and R² is methyl,
5 R³ is hydrogen.

Preferably R⁴ is hydrogen, phenyl, C₁₋₆alkyl or halo. More preferably tert-butyl, isopropyl or methyl.

10 Preferably R⁵ and R⁶ are independently selected from hydrogen; Het (preferably tetrahydropyranyl); C₃₋₆cycloalkyl optionally substituted by C₁₋₆alkyl; or by C₁₋₆alkyl optionally substituted by Het (preferably furyl), alkoxy, cyano or -NR^aR^b (where R^a and R^b which may be the same or different are hydrogen or C₁₋₆alkyl, or R^a and R^b together with the nitrogen atom to which they are attached may form a 4, 5 or 6-
15 membered saturated ring); or R⁵ and R⁶ together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, -CF₃, hydroxy, -OCF₃, C₁₋₄alkyl or C₁₋₄alkoxy.

20 More preferably R⁵ and R⁶ are independently selected from hydrogen, Het (preferably tetrahydropyranyl) or C₁₋₆alkyl; or R⁵ and R⁶ together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, -CF₃, hydroxy, -OCF₃, C₁₋₄alkyl or C₁₋₄alkoxy.

25

It will be appreciated that the present invention is intended to include compounds having any combination of the preferred groups listed hereinbefore.

Preferably

30 A is imidazole;

X is N;

R¹ is C₁₋₆alkyl, C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶,
-(CH₂)_nOR⁷, -O(CH₂)_n-Het (preferably imidazolyl), -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶,
-SO₂R⁷, -NR⁵SO₂R⁷, -R⁵COR⁷, -O(CH₂)_nCONR⁵R⁶, -NR⁵CO(CH₂)_nNR⁵R⁶ or
35 -C(O)R⁷;

R² is hydrogen, C₁₋₆alkyl or fluoro;

R³ is hydrogen or halo;

R⁴ is hydrogen, phenyl, C₁₋₆alkyl or halo;

R⁵ and R⁶ are independently selected from hydrogen, Het (preferably

5 tetrahydropyranyl) or C₁₋₆alkyl; or R⁵ and R⁶ together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, -CF₃, hydroxy, -OCF₃, C₁₋₄alkyl or C₁₋₄alkoxy;

R⁷ is selected from hydrogen and C₁₋₆alkyl;

10 Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C₁₋₆alkyl; and n is 1-4.

Compounds of formula (I) which are of special interest as agents useful in the
15 treatment or prophylaxis of disorders characterised by the overexpression of TGF- β are selected from the list:

4-{2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl}-2-(4-methanesulfonyl-phenyl)-pyridine (Example 84);

20 4-{4-[4-(2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 86);

N-(tetrahydropyran-4-yl)-4-(4-[2-isopropyl-5-[6-methyl-pyridin-2-yl]-1*H*-imidazol-4-yl]-pyridin-2-yl)-benzamide (Example 96);

4-{4-[4-(2-isopropyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 97);

25 4-(4-{4-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl}-benzyl)-dimethyl-amine (Example 105);

4-(4-{4-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl}-benzyl)-morpholine (Example 104);

30 N-(tetrahydropyran-4-yl)-4-(4-{2-*tert*-Butyl-5-[6-methyl-pyridin-2-yl]-1*H*-imidazol-4-yl]-pyridin-2-yl)-benzamide (Example 81);

(4-{4-[2-*tert*-Butyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl}-benzyl)-pyrrolidine (Example 103);

4-(2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridine (Example 108); and

35 4-{4-[4-(2-methyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 98);

and pharmaceutically acceptable salts, solvates and derivatives thereof.

For the avoidance of doubt, unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be
5 selected from a number of alternative groups, the selected groups may be the same or different.

For the avoidance of doubt, the term independently means that where more than one substituent is selected from a number of possible substituents, those substituents
10 may be the same or different.

As used herein the term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide, of the compound of formula (I), or any other compound which upon
15 administration to the recipient is capable of providing (directly or indirectly) the a compound of formula (I) or an active metabolite or residue thereof, e.g., a prodrug. Preferred pharmaceutically acceptable derivatives according to the invention are any pharmaceutically acceptable salts, solvates or prodrugs.

20 Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid salts, for example sodium, potassium, calcium, magnesium and tetraalkylammonium and the like, or mono- or di- basic salts with the appropriate acid for example organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic,
25 ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids and the like. Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well
30 as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Hereinafter, compounds, their pharmaceutically acceptable salts, their solvates and polymorphs, defined in any aspect of the invention (except intermediate compounds
35 in chemical processes) are referred to as "compounds of the invention".

The compounds of the invention may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included in the scope of the present invention.

Compounds of the invention may exist in the form of optical isomers, e.g.

5 diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

10

Since the compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the invention.

20 Compounds of the invention may be prepared, in known manner in a variety of ways. In the following reaction schemes and hereafter, unless otherwise stated R^1 to R^7 , X and n are as defined in the first aspect. These processes form further aspects of the invention.

25 Throughout the specification, general formulae are designated by Roman numerals (I), (II), (III), (IV) etc. Subsets of these general formulae are defined as (Ia), (Ib), (Ic) etc (IVa), (IVb), (IVc) etc.


Pyrazole Derivatives (IA)

30 Compounds of formula (IAa) may be prepared according to reaction scheme 1A from compounds of formula (IIA). Compounds of formula (IIA) are reacted with boron-containing compounds of formula (IIIA) using Suzuki coupling conditions (see Miyaura et al. Chem.Rev. 1995, 95: 2457) to give compounds of formula (IVA). Preferably reaction is carried out in the presence of a suitable base such as sodium carbonate, potassium carbonate, potassium hydroxide or sodium hydroxide, in the presence of a palladium or nickel catalyst, preferably at elevated temperature for a

35


period of between 30 minutes and 48 hours. Preferred catalysts include tetrakis(triphenylphosphine) palladium(0), palladium(II) acetate, dichlorobis(triphenylphosphine) palladium(II), tris(dibenzylideneacetone) dipalladium(0) and dichlorobis(triphenylphosphine) nickel. Compounds of formula (IVA) may be deprotected under acidic conditions (preferably hydrochloric acid) to give compounds of formula (IAa).

Scheme 1A




Compounds of formula (IAb) may be prepared according to reaction scheme 2A from compounds of formula (VA), by reacting compounds of formula (VA) with dimethylformamide dimethyl acetal and acetic acid in a solvent such as DMF at room temperature, followed by treatment with hydrazine.

Scheme 2A




- Compounds of formula (VA) may be prepared using Suzuki coupling methodology (see reaction scheme 1A) from compounds of formula (VIA) according to reaction scheme 3A. Compounds of formula (VIA) may in turn be prepared in two steps from 2-bromo-4-pyridinecarboxylic acid.

Scheme 3A




- Compounds of formula (IVAA), i.e. compounds of formula (IVA) (see reaction scheme 1A) where R^1 is OR (where R is C_{1-6} alkyl, $-(CH_2)_nOR^7$, $-(CH_2)_nNR^5R^6$ or $-(CH_2)_nHet$), may be prepared from compounds of formula (VIA) according to reaction scheme 4A, by reaction with RX (where X is a leaving group such as halogen) in the presence of base such as potassium carbonate or sodium hydride in a solvent such as dimethylformamide.

Scheme 4A

Compounds of formula (IVAb), i.e. compounds of formula (IVA) (see reaction scheme


- 5 1A) where R^1 is $CONR^5R^6$, may be prepared according to reaction scheme 5A, by reacting compounds of formula (VIIIa) with R^5R^6NH preferably in the presence of hydroxybenzotriazole and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride.

10 Scheme 5A

Compounds of formula (IVAc), i.e. compounds of formula (IVA) (see reaction scheme 1A) where R^1 is $-CH_2NR^5R^6$, may be prepared according to reaction scheme 6A by

- 15 reacting compounds of formula (IXA) with R^5R^6NH in the presence of a reducing agent, preferably sodium triacetoxyborohydride in acetic acid, in a solvent such as dichloroethane at room temperature.


Scheme 6A




Compounds of formula (VIIA), (VIIIa) and (IXA) may be prepared by Suzuki coupling of compounds of formula (IIA) and the appropriate boron-containing compound, using conditions analogous to those described for reaction scheme 1A.

The skilled person will appreciate that compounds of formula (IVAa), (IVAb) and (IVAc) may also be prepared directly by Suzuki coupling of compounds of formula (IIA) with the appropriate boron-containing compound.

Compounds of formula (IIA) may be prepared according to reaction scheme 7A. Firstly, 2-bromo-4-methylpyridine may be coupled to compounds of formula (XA) to give compounds of formula (XIA). Preferred reaction conditions comprise treatment with a base such as sodium bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide in tetrahydrofuran at a range of temperature from -70°C to 0°C . Compounds of formula (XIA) may then be reacted with dimethylformamide dimethyl acetal and acetic acid in a solvent such as DMF at room temperature followed by treatment with hydrazine to give compounds of formula (XIIA) where R^2 is hydrogen. To prepare compounds of formula (XIIA) where R^4 is methyl, N,N-dimethylacetamide acetal is used instead of dimethylformamide dimethyl acetal. Reaction of compounds of formula (XIIA) with trityl chloride gives compounds of formula (IIA).

Scheme 7ATriazole Derivatives (IB)


- 5 Compounds of formula (IB) may be prepared from compounds of formula (IIB) by treatment with an azide source according to reaction scheme 1B. Preferred reaction conditions comprise treating compounds of formula (IIB) with trimethylsilylazide at elevated temperature in a suitable solvent such as dimethylformamide.

10 Scheme 1B


Compounds of formula (IIB) may be prepared by reacting compounds of formula (IIIB) (where Y is a leaving group such as halogen preferably chlorine) with boronic

acid derivatives of formula (IVB) according to reaction scheme 2B. Preferred conditions are those developed by Miyaura et al (Chem.Rev. 1995, 95: 2457), typically comprising reaction inert solvent in the presence of a base and a palladium or nickel catalyst at a temperature of between room temperature and 130°C for a period between 30 minutes and 48 hours. Suitable bases include sodium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide. Suitable catalysts include tetrakis(triphenylphosphine) palladium(0), palladium(II) acetate, dichlorobis(triphenylphosphine) palladium(II), tris(dibenzylideneacetone) dipalladium(0) and dichlorobis(triphenylphosphine) nickel.


Scheme 2B



Compounds of formula (IIB) may be prepared by Sonagashira coupling of compounds of formula (VB) (where preferably Y is chlorine and Z is iodine) with compounds of formula (VIB) according to reaction scheme 3. Preferred reaction conditions comprise reaction in an inert solvent in the presence of a base and a palladium catalyst at a temperature of between room temperature and 80°C, for a period of between 30 minutes and 48 hours. Suitable bases include TMEDA or triethyl amine. Suitable palladium catalysts include tetrakis(triphenylphosphine) palladium(0) and dichlorobis(triphenylphosphine) palladium(II).

Scheme 3B

- Compounds of formula (VIB) may be prepared according to reaction scheme 4B
- 5 where Y¹ in compounds of formula (VII B) is a leaving group, preferably bromine. Preferred reaction conditions for the preparation of compounds of formula (VIII B) comprise treating compounds of formula (VII B) with trimethylsilylacetylene in the presence of TMEDA and copper iodide under palladium catalysis in an inert solvent such as tetrahydrofuran at elevated temperature. The trimethylsilyl group may be removed by treating compounds of formula (VIII B) with a base such as potassium carbonate in a protic solvent such as methanol.
- 10


Scheme 4B

15

- Compounds of formula (II Ba), i.e. compounds of formula (II B) where R¹ is -O(CH₂)₂NR⁵R⁶, may be prepared from compounds of formula (III B) (where Y is preferably chlorine) according to reaction scheme 5B. Compounds of formula (III B) may be reacted with compounds of formula (IX B) to give compounds of formula (II Ba) in one step. Alternatively compounds of formula (III B) may firstly be reacted
- 20

with 4-hydroxy-phenyl boronic acid, followed by alkylation with $R^5R^6N(CH_2)_2Cl$ in the presence of a base such as potassium carbonate or sodium hydride in a solvent such as dimethylformamide.


5 Scheme 5B



Compounds of formula (IIBb), i.e. compounds of general formula (IIB) where R¹ is -CH₂NR⁵R⁶, may be prepared according to reaction scheme 6B. Compounds of formula (IIIB) (where Y is preferably chlorine) may be reacted with 4-formylphenyl boronic acid using analogous conditions to reaction scheme 2 to give compounds of formula (XB). Compounds of formula (XB) may then be reacted with R⁵R⁶NH in the presence of a reducing agent, such as sodium cyanoborohydride in acetic acid at room temperature, to give compounds of formula (IIBb).


15

Scheme 6B




Imidazopyridine Derivatives (IC)

Compounds of formula (IC) may be prepared from compounds of formula (IIC) according to reaction scheme 1C, by reacting compounds of formula (IIC) with compounds of formula (IIIC). Preferred reaction conditions comprise boron coupling of compounds of formula (IIIC) where Y is $-B(OH)_2$ or 4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl cyclic derivative, with a compound of formula (IIC) in the presence of a suitable palladium catalysis (preferably $Pd(PPh_3)_4$) and a suitable base (preferably sodium carbonate) in an inert solvent (preferably 1,2-dimethoxyethane) at elevated temperature.

Scheme 1C

Compounds of formula (ICa), i.e. compounds of formula (IC) where R^1 is $-CH_2NR^5R^6$, may be prepared by reductive amination of compounds of formula (IVC) according to reaction scheme 2C. Preferred reaction conditions comprise reacting (IVC) with HNR^5R^6 in the presence of $NaBH(OAc)_3$, in a suitable solvent (preferably dichloromethane) at room temperature.


Scheme 2C



Compounds of formula (IIIC) are available from commercial sources or may be prepared by methods analogous to those described in the Examples section hereinafter.


Compounds of formula (ICb), i.e. compounds of formula (IC) where R^1 is $-NR^5R^6$, may be prepared according to reaction scheme 3C by reacting compounds of formula (ICc), i.e. compounds of formula (IC) where R^1 is bromine, with HNR^5R^6 in the presence of a catalyst system preferably tris(dibenzylideneacetone)dipalladium(0) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (Binap) in potassium tert-butoxide in a suitable solvent such as toluene at elevated temperature.

Scheme 3C




- Compounds of formula (ICd), i.e. compounds of formula (IC) where R^1 is $-OCH_2CH_2NR^5R^6$, may be prepared according to reaction scheme 4C by reacting
- 5 compounds of formula (VC) with 1,2-dibromoethane in the presence of a base preferably potassium carbonate in a suitable solvent, such as acetone, at elevated temperature. Treatment with HNR^5R^6 in a suitable solvent such as tetrahydrofuran at elevated temperature gives (ICd).

10 Scheme 4C




Compounds of formula (ICe), i.e. compounds of general formula (IC) where R^1 is $-CONR^5R^6$, may be prepared according to reaction scheme 5C. Compounds of

formula (VIC) (where R is methyl or ethyl) are firstly saponified by heating with sodium hydroxide in methanol, followed by conversion of the resulting carboxylic acid to amide (ICe). Preferred reaction conditions comprise treating the intermediate carboxylic acid with HNR^5R^6 in the presence of HOBT, EDCI and a suitable base such as triethylamine in a suitable solvent such as dimethylformamide at room temperature.

Scheme 5C

Compounds of formula (ICg), i.e. compounds of general formula (IC) where R^1 is $-\text{NHSO}_2\text{CF}_3$, may be prepared in two steps according to reaction scheme 6C. Firstly the acetyl group is removed from compounds of formula (IC_h) by treatment with sodium hydroxide in methanol at elevated temperature. The resulting amine is then treated with $\text{CF}_3\text{SO}_2\text{Cl}$ preferably in the presence of a base such as triethylamine in a suitable solvent such as dichloromethane at room temperature.


Scheme 6C



It will be apparent to the skilled person that compounds of formula (IC) may also be prepared by introducing R¹ before formation of the imidazopyridine. For instance, compounds of formula (ICi), i.e. compounds of formula (IC) where R¹ is morpholine, X is N and R³ is H may be prepared according to reaction scheme 7C.


Scheme 7C

22




- Compounds of formula (IIC) (see Scheme 1C) may be prepared in two steps according to reaction scheme 8C. Compounds of formula (VIIC) are firstly reacted with a suitable polymer-supported bromine reagent, such as polymer-supported pyridinium perbromide, in a suitable solvent such as dichloromethane at room temperature. Treatment with a compound of formula (VIIIC) in a suitable solvent such as ethanol at elevated temperature gives compounds of formula (IIC).

Scheme 8C



Compounds of formula (VIIC) may be prepared according to reaction scheme 9C by reacting 2-bromo-4-methylpyridine with compounds of formula (IXC) in the presence of a suitable base such as sodium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran at -78°C to -30°C .

Scheme 9C




Imidazole Derivatives (ID)

Compounds of formula (ID) may be prepared according to Scheme 1D. Compounds of formula (IID) may be treated with sodium nitrite in HCl to give compounds of formula (IIID). Compounds of formula (IIID) may then be condensed with a suitably substituted aldehyde and ammonium acetate followed by treatment with triethylphosphite to give compounds of formula (IVD) according to the method outlined in US Pat. 5,656,644. Boronic acid coupling gives compounds of formula (ID). Preferred coupling conditions are those developed by Miyaura et al (Chem. Rev. 1995, 95: 2457), typically comprising reaction in an inert solvent in the presence of a base and a palladium or nickel catalyst at temperature between room temperature and 130°C for a period between 30 minutes and 48 hours. Suitable bases include sodium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide. Suitable catalysts include tetrakis(triphenylphosphine) palladium(0), palladium(II)


acetate, dichlorobis(triphenylphosphine) palladium(II), tris(dibenzylideneacetone) dipalladium(0) and dichlorobis(triphenylphosphine) nickel.

Scheme 1D



Compounds of formula (IDa), i.e. compounds of formula (I) where X is N, R¹ is -CH₂NR⁵R⁶ and R³ is hydrogen, may be prepared in one step according to scheme 2D from compounds of formula (VD).


Scheme 2D



Compounds of formula (IDb), i.e. compounds of formula (ID) where X is N, R¹ is -NR⁵R⁶ and R³ is hydrogen, may be prepared according to reaction scheme 3D by reacting compounds of formula (VID) with HNR⁵R⁶ in the presence of a catalyst system preferably tris(dibenzylidene acetone)dipalladium(0) and 2,2'-

bis(diphenylphosphino)-1,1'-binaphthyl (Binap) in potassium tert-butoxide in a suitable solvent such as toluene at elevated temperature.

Scheme 3D




5

Compounds of formula (IDc), i.e. compounds of formula (ID) where X is N, R¹ is -OCH₂CH₂NR⁵R⁶ and R³ is hydrogen, may be prepared according to reaction scheme 4D by reacting compounds of formula (VIID) with 1,2-dibromoethane in the presence of a base preferably potassium carbonate in a suitable solvent, such as acetone, at elevated temperature. Treatment with HNR⁵R⁶ in a suitable solvent such as tetrahydrofuran at elevated temperature gives (IDc).

10

Scheme 4D




15

Compounds of formula (IDd), i.e. compounds of formula (ID) where X is N, R¹ is -OCH₂-Het and R³ is hydrogen, may be prepared according to reaction scheme 5D by reacting compounds of formula (VIID) with compounds of formula (IXD) in the presence of a base (preferably sodium hydride) in a suitable solvent, such as DMF, at room temperature.


20

Scheme 5D




- Compounds of formula (IDe), i.e. compounds of general formula (ID) where X is N, R¹ is -CONR⁵R⁶ and R³ is hydrogen, may be prepared according to reaction scheme 6D. Compounds of formula (XD) (where R is methyl or ethyl) are saponified by
- 5 heating with sodium hydroxide in methanol followed by conversion of the resulting carboxylic acid to amide (IDe). Preferred reaction conditions comprise treating the intermediate carboxylic acid with HNR⁵R⁶ in the presence of hydroxybenzotriazole (HOBT), 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI) and
- 10 dimethylformamide at room temperature.

Scheme 6D



- 15 Compounds of formula (ID) where X is N and R¹ is -NHSO₂CF₃ or -NHCOCF₃, may be prepared from common intermediate of formula (XID) according to reaction scheme 7D. Firstly the acetyl group is removed from compounds of formula (XID) by treatment with sodium hydroxide in methanol at elevated temperature. The resulting amine is then treated with CF₃SO₂Cl or CF₃COCl preferably in the presence of a
- 20 base such as triethylamine in a suitable solvent such as dichloromethane at room temperature.


Scheme 7D



Aminothiazole Derivatives (IE)


- Compounds of formula (IEa), i.e. compounds of general formula (IE) where A is S, B is N and R^4 is NH_2 , may be prepared by reacting compounds of formula (IIE) with a suitable polymer-supported bromine reagent, such as polymer-supported pyridinium perbromide, followed by treatment with thiourea in a suitable solvent such as ethanol, preferably at elevated temperatures (see reaction scheme 1E).

10 Scheme 1E




- Compounds of formula (IEb), i.e. compounds of general formula (IE) where A is N, B is S and R^4 is NH_2 , may be prepared by reacting compounds of formula (IIIE) under analogous conditions to reaction scheme 1E (see reaction scheme 2E).

Scheme 2E




Compounds of formula (II E) may be prepared by reacting compounds of formula (IV E) with compounds of formula (V E) where Y is a boron containing moiety such as $-B(OH)_2$ or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl according to reaction scheme 3E. Preferred conditions comprise reaction with a suitable catalyst such as tetrakis(triphenylphosphine) palladium (0), in the presence of a suitable base such as sodium carbonate in a suitable solvent such as DME at elevated temperature.

10 Scheme 3E




Alternatively compounds of formula (II E) may be prepared by reacting compounds of formula (VI E) with compounds of formula (VII E) according to reaction scheme 4E. Preferred reaction conditions comprise reacting (VI E) with sodium bis-(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran at low temperature, preferably -78°C .

Scheme 4E



Compounds of formula (IIIE) may be prepared according to reaction scheme 5E by reacting compounds of formula (VIIIE) with compounds of formula (VE) (where Y is as defined for reaction scheme 3E) using analogous reaction conditions to those of reaction scheme 3E.


Scheme 5E



Alternatively compounds of formula (IIIE) may be prepared according to reaction scheme 6E by reacting compounds of formula (IXE) with compounds of formula (XE) in the presence of a suitable base such as cesium carbonate in a suitable solvent such as tetrahydrofuran and isopropanol at room temperature.

Scheme 6E


30



Compounds of formula (VIII Ea), i.e. compounds of general formula (VIII E) (see scheme 5E) where X is N, R² is methyl and R³ is hydrogen, may be prepared

- 5 according to reaction scheme 7E. Preferred conditions comprise reacting 2,6-lutidine with a strong base such as n-butyllithium or sodium bis-(trimethylsilyl) amide at low temperature, followed by addition of 2-bromo-N-methoxy-N-methyl-4-pyridinecarboxamide.


10 Scheme 7E



- Compounds of formula (IXE) may be prepared in two steps according to reaction scheme 8E. Preferred reaction conditions for the first step are analogous to those described for reaction scheme 3E. Preferred reaction conditions for the second step
- 15 comprise reacting compounds of formula (XIE) with aniline and diphenylphosphite in a suitable solvent such as isopropanol at room temperature.

Scheme 8E

31



Compounds of general formula (IE) may also be prepared using solid supported chemistry.

5.


Compounds of formula (IEc), i.e. compounds of general formula (I) where A is S, B is N, R¹ is -OR (where R is for example -(CH₂)_n-Het or -CH₂CONR⁵R⁶) and R⁴ is NH₂, may be prepared from solid supported compounds of formula (XIIE) by reaction with RX (where X is a suitable leaving group such as chlorine) followed by cleavage

10

under acidic conditions from the solid support, according to reaction scheme 9E. Preferred conditions comprise treating (XII E) with RX under basic conditions such as potassium carbonate in a suitable solvent such as DMSO at elevated temperature. Preferred cleavage conditions are trifluoroacetic acid in a suitable solvent such as dichloromethane at room temperature.

15


Scheme 9E



Compounds of formula (IEd), i.e. compounds of general formula (IE) where A is S, B is N, R¹ is -CH₂NR⁵R⁶ and R⁴ is NH₂, may be prepared from solid supported


20

compounds of formula (XIIIE) according to reaction scheme 10E. Preferred reaction conditions comprise treating (XIIIE) with HNR^5R^6 in trimethylorthoformate and addition of a reducing agent, such as sodium cyanoborohydride in acetic acid at elevated temperature. Cleavage from the solid support using trifluoroacetic acid in dichloromethane gives compounds of formula (IEd).

Scheme 10E


Compounds of formula (IEe), i.e. compounds of general formula (IE) where A is S, B is N, R^1 is $-\text{C}(\text{O})\text{NR}^5\text{R}^6$ and R^4 is NH_2 , may be prepared from solid supported compounds of formula (XIVE) according to reaction scheme 11E. Preferred reaction conditions comprise treating (XIVE) with HNR^5R^6 , hydroxybenzotriazole and diisopropylcarbodiimide. Cleavage from the solid support using trifluoroacetic acid in dichloromethane gives compounds of formula (IEe).

Scheme 11E




Compounds of formula (XIIe), (XIIIe) and (XIVe) may be prepared according to reaction scheme 12E from compounds of formula (XVe) and the appropriate arylboronic acid (XVIE), where Z is -OH, -CHO or -CO₂H respectively.

Scheme 12E



Compounds of formula (XVe) may be prepared from solid-phase synthesis according to reaction scheme 13E. Compounds of formula (XVIE) may be prepared by treating compounds of formula (IVE) (see scheme 3E) with a suitable polymer-supported bromine reagent, such as polymer-supported pyridinium perbromide. Treatment of a resin bound thiourea with a dioxane solution of compounds of formula (XVI) gives the compounds (XV) using general conditions described in the literature (Kearney P.C., J. Org. Chem., (1998), 63, 196).

Scheme 13E



- 5 Further details for the preparation of compounds of formula (I) are found in the examples section hereinafter.

The compounds of the invention may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds. Libraries of compounds of the invention may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art. Thus according to a further aspect there is provided a compound library comprising at least 2 compounds of the invention.

15

Activation of the TGF- β 1 axis and expansion of extracellular matrix are early and persistent contributors to the development and progression of chronic renal disease and vascular disease. Border W.A., et al, N. Engl. J. Med., 1994; 331(19), 1286-92. Further, TGF- β 1 plays a role in the formation of fibronectin and plasminogen activator inhibitor-1, components of sclerotic deposits, through the action of smad3 phosphorylation by the TGF- β 1 receptor ALK5. Zhang Y., et al, Nature, 1998; 394(6696), 909-13; Usui T., et al, Invest. Ophthalmol. Vis. Sci., 1998; 39(11), 1981-9.

Progressive fibrosis in the kidney and cardiovascular system is a major cause of suffering and death and an important contributor to the cost of health care. TGF- β 1 has been implicated in many renal fibrotic disorders. Border W.A., et al, N. Engl. J.

25

Med., 1994; 331(19), 1286-92. TGF- β 1 is elevated in acute and chronic glomerulonephritis Yoshioka K., et al, Lab. Invest., 1993; 68(2), 154-63, diabetic nephropathy Yamamoto, T., et al, 1993, PNAS 90, 1814-1818., allograft rejection, HIV nephropathy and angiotensin-induced nephropathy Border W.A., et al, N. Engl. J. Med., 1994; 331(19), 1286-92. In these diseases the levels of TGF- β 1 expression coincide with the production of extracellular matrix. Three lines of evidence suggest a causal relationship between TGF- β 1 and the production of matrix. First, normal glomeruli, mesangial cells and non-renal cells can be induced to produce extracellular-matrix protein and inhibit protease activity by exogenous TGF- β 1 in vitro. Second, neutralizing anti-bodies against TGF- β 1 can prevent the accumulation of extracellular matrix in nephritic rats. Third, TGF- β 1 transgenic mice or in vivo transfection of the TGF- β 1 gene into normal rat kidneys resulted in the rapid development of glomerulosclerosis. Kopp J.B., et al, Lab. Invest., 1996; 74(6), 991-1003. Thus, inhibition of TGF- β 1 activity is indicated as a therapeutic intervention in chronic renal disease.

TGF- β 1 and its receptors are increased in injured blood vessels and are indicated in neointima formation following balloon angioplasty Saltis J., et al, Clin. Exp. Pharmacol. Physiol., 1996; 23(3), 193-200. In addition TGF- β 1 is a potent stimulator of smooth muscle cell ("SMC") migration in vitro and migration of SMC in the arterial wall is a contributing factor in the pathogenesis of atherosclerosis and restenosis. Moreover, in multivariate analysis of the endothelial cell products against total cholesterol, TGF- β receptor ALK5 correlated with total cholesterol ($P < 0.001$) Blann A.D., et al, Atherosclerosis, 1996; 120(1-2), 221-6. Furthermore, SMC derived from human atherosclerotic lesions have an increased ALK5/TGF- β type II receptor ratio. Because TGF- β 1 is over-expressed in fibroproliferative vascular lesions, receptor-variant cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components McCaffrey T.A., et al, Jr., J. Clin. Invest., 1995; 96(6), 2667-75. TGF- β 1 was immunolocalized to non-foamy macrophages in atherosclerotic lesions where active matrix synthesis occurs, suggesting that non-foamy macrophages may participate in modulating matrix gene expression in atherosclerotic remodelling via a TGF- β -dependent mechanism. Therefore, inhibiting the action of TGF- β 1 on ALK5 is also indicated in atherosclerosis and restenosis.

- TGF- β is also indicated in wound repair. Neutralizing antibodies to TGF- β 1 have been used in a number of models to illustrate that inhibition of TGF- β 1 signalling is beneficial in restoring function after injury by limiting excessive scar formation during the healing process. For example, neutralizing antibodies to TGF- β 1 and TGF- β 2
- 5 reduced scar formation and improved the cytoarchitecture of the neodermis by reducing the number of monocytes and macrophages as well as decreasing dermal fibronectin and collagen deposition in rats Shah M., J. Cell. Sci., 1995, 108, 985-1002. Moreover, TGF- β antibodies also improve healing of corneal wounds in rabbits Moller-Pedersen T., Curr. Eye Res., 1998, 17, 736-747, and accelerate
- 10 wound healing of gastric ulcers in the rat, Ernst H., Gut, 1996, 39, 172-175. These data strongly suggest that limiting the activity of TGF- β would be beneficial in many tissues and suggest that any disease with chronic elevation of TGF- β would benefit by inhibiting smad2 and smad3 signalling pathways.
- 15 TGF- β is also implicated in peritoneal adhesions Saed G.M., et al, Wound Repair Regeneration, 1999 Nov-Dec, 7(6), 504-510. Therefore, inhibitors of ALK5 would be beneficial in preventing peritoneal and sub-dermal fibrotic adhesions following surgical procedures.
- 20 TGF- β is also implicated in photoaging of the skin (see Fisher GJ. Kang SW. Varani J. Bata-Csorgo Z. Wan.YS. Data S. Voorhees JJ. , Mechanisms of photoaging and chronological skin ageing, Archives of Dermatology, 138(11):1462-1470, 2002 Nov. and Schwartz E. Sapadin AN. Kligman LH. "Ultraviolet B radiation increases steady state mRNA levels for cytokines and integrins in hairless mouse skin- modulation by
- 25 topical tretinoin", Archives if Dermatological Research, 290(3):137-144, 1998 Mar.)

Therefore according to a further aspect, the invention provides the use of a compound defined in the first aspect in the preparation of a medicament for treating or preventing a disease or condition mediated by ALK-5 inhibition.

30

- Preferably the disease or condition mediated by ALK-5 inhibition is selected from the list: chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers (including diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers), ocular disorders, corneal
- 35 wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease,

atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to kidney fibrosis, lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis, primary biliary cirrhosis, restenosis,
5 retroperitoneal fibrosis, mesenteric fibrosis, endometriosis, keloids, cancer, abnormal bone function, inflammatory disorders, scarring and photaging of the skin.

More preferably the disease or condition mediated by ALK-5 inhibition is fibrosis.
Preferably kidney fibrosis.

10

It will be appreciated that references herein to treatment extend to prophylaxis as well as the treatment of established conditions.

15

Compounds of the invention may be administered in combination with other therapeutic agents, for example antiviral agents for liver diseases, or in combination with ACE inhibitors or angiotensin II receptor antagonists for kidney diseases.

20

The compounds of the invention may be administered in conventional dosage forms prepared by combining a compound of the invention with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

25

The pharmaceutical compositions of the invention may be formulated for administration by any route, and include those in a form adapted for oral, topical or parenteral administration to mammals including humans.

30

The compositions may be formulated for administration by any route. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

35

The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as

preservatives, solvents to assist drug penetration and emollients in ointments and creams.

5 The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

10 Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as
15 sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as
20 suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol;
25 preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

30

For parenteral administration, fluid unit dosage forms are prepared utilising the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection
35 and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilised powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

It will be recognised by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of the invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of the invention given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

No toxicological effects are indicated when a compound of the invention is administered in the above-mentioned dosage range.

All publications, including, but not limited to, patents and patent applications cited in this specification, are herein incorporated by reference as if each individual

publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

It will be appreciated that the invention includes the following further aspects. The preferred embodiments described for the first aspect extend these further aspects:

- i) a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent;
- 10 ii) a compound of the invention for use as a medicament;
- 15 iii) a method of treatment or prophylaxis of a disorder selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers (including diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers), ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to kidney fibrosis, lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced
20 hepatitis, haemochromatosis, primary biliary cirrhosis, restenosis, retroperitoneal fibrosis, mesenteric fibrosis, endometriosis, keloids, cancer, abnormal bone function, inflammatory disorders, scarring and photoaging of the skin, in mammals, which comprises administration to the mammal in need of such treatment, an effective amount of a compound of the invention; and
25 iv) a combination of a compound of the invention with an ACE inhibitor or an angiotensin II receptor antagonist.

According to a further aspect, the invention provides a compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof,
30 wherein

X is N or CH;

A is selected from the list: furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazole, isoxazole,
35 oxazoline, oxazolidine, thiazole, isothiazole, thiadiazole, benzofuran, indole,

isoindole, indazole, imidazopyridine, quinazoline, quinoline, isoquinoline and triazole;

R¹ is selected from H, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro

C₁₋₆alkyl, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁵,

5 -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -CO(CH₂)_nNR⁵R⁶, -SO₂R⁵, -SO₂NR⁵R⁶,
-NR⁵SO₂R⁵ and -NR⁵COR⁶;

R² is selected from H, C₁₋₆alkyl, halo, CN or perfluoroC₁₋₆alkyl;

R³ is selected from H or halo;

R⁴ is selected from H, halo, C₁₋₆alkyl or -NR⁵R⁶;

10 R⁵ and R⁶ are independently selected from H or C₁₋₆alkyl; or R⁵R⁶ together with the
atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or
unsaturated ring which may contain one or more heteroatoms selected from
N, S or O, and wherein the ring may be further substituted by one or more
substituents selected from halo (such as fluoro, chloro, bromo), -CN, -CF₃, -

15 OH, -OCF₃, C₁₋₆ alkyl and C₁₋₆ alkoxy; and

n is 1-4;

with the provisos that :

a) when A is thiazole (wherein the thiazole sulfur is on the same side as the 4-pyridyl
moiety); X is N; R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, cyano, perfluoroC₁₋₆alkyl
20 or perfluoroC₁₋₆alkoxy; R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl;
and R³ is hydrogen or halo; then R⁴ is not NH₂; and

b) when X is N, A is pyrazole (where the ring containing X is attached to the pyrazole
ring at carbon atom next to a pyrazole ring nitrogen), R² is hydrogen then R³ is not
hydrogen.

25

The following examples illustrate the present invention.

Abbreviations

	Binap	2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl
30	CH ₂ Cl ₂	dichloromethane
	CuI	copper(I) iodide
	DCE	dichloroethane
	DMF	dimethylformamide
	DMF.DMA	- dimethylformamide dimethylacetal
35	DME	1,2-Dimethoxyethane
	DMSO	dimethylsulfoxide

	EDCI	1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
	EtOAc	ethyl acetate
	Et ₂ O	diethyl oxide
	EtOH	ethanol
5	Et ₃ N	triethylamine
	Fmoc-NCS	fluoromethylcarbonyl isothiocyanate
	HOBT	hydroxybenzotriazole
	K ₂ CO ₃	potassium carbonate
	KMnO ₄	potassium permanganate
10	LiAlH ₄	lithium aluminium hydride
	MeCN	acetonitrile
	MeOH	methanol
	Na ₂ CO ₃	sodium carbonate
	NaH	sodium hydride
15	NaHB(OAc) ₃	sodium triacetoxyborohydride
	NaHCO ₃	sodium hydrogen carbonate
	NaHMDS	sodium bis(trimethylsilyl)amide
	NaNO ₂	sodium nitrite
	NaOH	sodium hydroxide
20	NH ₄ Cl	ammonium chloride
	Na ₂ SO ₄	sodium sulfate
	Pd ₂ (dba) ₃	tris(dibenzylideneacetone)dipalladium(0)
	Pd(PPh ₃) ₄	tetrakis(triphenylphosphine)palladium (0)
	PTS	para-toluenesulfonic acid
25	TEA	triethylamine
	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	TMEDA	N,N,N',N'- Tetramethylethylenediamine
	TMS	trimethylsilyl
30	TMSN ₃	trimethylsilyl azide
	t-BuOK	potassium <i>tert</i> -butoxide

Intermediate 1: 2-Chloro-4-iodo-pyridine

- To a solution of 4-amino-2-chloro-pyridine (8.09g, 63 mmol, 1eq) in water (150mL)
 35 cooled to 0°C was added concentrated 98% HCl. A solution of sodium nitrite (5.65g,
 82mmol, 1.3eq) in water (50mL) was added slowly at -10°C and the mixture was

stirred at this temperature for 40 min. A solution of potassium iodide (12.55g, 75.6mmol, 1.2eq) in water (50mL) was added and the resulting mixture was stirred at 0°C overnight. After treatment with NaOH (35%) and extraction with ethyl acetate, the organic phases were combined and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica gel (eluent : CH₂Cl₂ then CH₂Cl₂/ CH₃OH 99 : 1) to give the title compound as an orange solid (9.5g, 63%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.99 (1H, d), 7.68 (1H, s), 7.52 (1H, d); (GC-MS) m/z : 239.


10 Intermediate 2: 2-Methyl-6-trimethylsilanylethynyl-pyridine

To a solution of 2-bromo-4-methyl-pyridine (25g, 0.15 mol) in dry THF (200mL) were added TMEDA (200mL) and TMS-acetylene (100mL, excess) under N₂. The resulting mixture was degassed with nitrogen for 10 min and then tetrakis(triphenylphosphine) palladium(0) (3.7mmol, 4.3g) and copper iodide (14.7mmol, 2.8g) were added and the mixture was heated at 60°C for 18h. The reaction mixture was concentrated and the residue partitioned between ethyl acetate / water. The organic phase was dried over Na₂SO₄ and filtered. Evaporation of the solvent in vacuo gave a crude product which was purified by chromatography on silica gel (CH₂Cl₂) to give the title compound (18.4g, 65%) as a black oil; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.58-7.49 (m, 1H), 7.30 (d, 1H), 7.10 (d, 1H), 2.56 (s, 3H), 0.28 (s, 9H).

Intermediate 3: 2-Ethynyl-6-methyl-pyridine

To a solution of intermediate 2 (18.4g, 0.097mol) in MeOH (100 ml) was added potassium carbonate (4eq, 0.39mol, 53.7g) and the reaction mixture was stirred at rt for 30 min. The solvent was removed and the residue was partitioned between ethyl acetate / water. The organic layer was dried over Na₂SO₄, filtered and the solvent evaporated under reduced pressure to give the title compound (8.75g, 77%) as a brown oil; ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.45-7.34 (m, 1H), 7.14 (d, 1H), 6.98 (d, 1H), 2.97 (s, 1H), 2.40 (s, 3H).


30 Intermediate 4: 6-Methyl-2-[(2-chloro-pyridin-4-yl)-ethynyl]-pyridine



To a solution of intermediate 1 (1.85g, 7.74mmol) in dry THF (40mL) were added under nitrogen TMEDA (20mL) and intermediate 3 (1.1eq, 1g, 8.51mmol). The resulting mixture was degassed with nitrogen for ten mins,

- 5 tetrakis(triphenylphosphine)palladium(0) (0.537g, 0.464mmol) and copper iodide (0.177g, 0.928 mmol) were added and the mixture was heated at 60°C for 4hours. The mixture was poured into a saturated solution of NH₄Cl and extracted with EtOAc. The organic phase was dried over Na₂SO₄ and filtered. The solvent was removed under reduced pressure and the residue was purified by chromatography on silica
10 gel (CH₂Cl₂/EtOAc 90:10) to afford the title compound as a beige solid (1.54g, 86.4%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.29 (d, 1H), 7.52 (t, 1H), 7.39 (s, 1H), 7.34-7.24 (m, 2H), 7.10 (d, 1H), 2.50 (s, 3H).

Intermediate 5: 2-[2-(4-methylsulfonylphenyl)-pyridin-4-yl]-ethynyl]-6-methyl-pyridine




15

- A solution of intermediate 4 (1g, 4.37mmol), 4-(methylsulfonyl)phenyl boronic acid (1.14g, 5.7 mmol), tetrakis(triphenylphosphine) palladium(0) (0.118 g, 0.1mmol) and aqueous sodium carbonate 2M (8.6mL, 17.2mmol) in toluene (30mL) and EtOH (10mL) under nitrogen was stirred under reflux for 6 h. The mixture was hydrolysed
20 with water, extracted with ethyl acetate and the combined organic phases were washed with water and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica gel (eluent : CH₂Cl₂/CH₃OH 98:2) to give the title compound as a yellow oil (0.7g, 46%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.66 (d, 1H), 8.14 (d, 2H), 7.98 (d, 2H),
25 7.90 (s, 1H), 7.56 (t, 1H), 7.43-7.32 (m, 2H), 7.12 (d, 1H), 3.03 (s, 3H), 2.50 (s, 3H) ; [APCI MS] m/z 349 (MH⁺).

30

The following compounds of formula (IIBc) were prepared by methods analogous to that described for intermediate 5 using the appropriate boronic acid derivative (see Table 1).

45




(IIbC)

Table 1


Int.	R¹	From intermediates :	Physical data
6	methoxy	4	APCI MS m/z 301 (MH⁺)
7	tetrahydropyran-4-ylaminocarbonyl	4, 33	APCI MS m/z 398 (MH⁺)
8	hydroxy	4	APCI MS m/z 287 (MH⁺)
9	ethyl	4	APCI MS m/z 299 (MH⁺)
10	chloro	4	APCI MS m/z 306 (MH⁺)
11	trifluoromethoxy	4	APCI MS m/z 355 (MH⁺)
12	2-(pyrrolidino)ethoxy	4, 29	APCI MS m/z 384 (MH⁺)
13	fluoro	4	APCI MS m/z 289 (MH⁺)
14	formyl	4	APCI MS m/z 299 (MH⁺)

5 Intermediate 15: 4-{4-[4-(6-Methyl-pyridin-2-ylethynyl)-pyridin-2-yl]-benzyl}-morpholine



To a solution of intermediate 14 (0.45g, 1.5mmol) in dichloroethane (40ml) were added morpholine (0.9g, 6mmol), sodium triacetoxymethylborohydride (1.2g, 6mmol) and acetic acid (0.27g, 4mmol). The mixture was stirred at room temperature for 6 hours and then poured into ice and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound as a yellow oil (0.55g, quantitative); [APCI MS] m/z 370 (MH⁺).

15 Intermediate 16: N,N-dimethyl-2-[(4-{4-(6-methyl-pyridin-2-yl-ethynyl)-pyridin-2-yl}phenyl)oxy]ethanamine



To a solution of intermediate 8 (0.572g, 2mmol) in acetone (20ml) were added 2-chloro-N,N-dimethylethanamine hydrochloride (0.374g, 2.6mmol) and potassium carbonate (0.822g, 6mmol) and the mixture was stirred under reflux overnight. The reaction mixture was filtered and concentrated under reduced pressure. The residue was poured into water and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound as a brown oil (0.7g, 98%); [APCI MS] m/z= 358 (MH⁺).

10 Intermediate 17: 3-chloro-4-fluoro-benzoic acid ethyl ester

To a solution of 3-chloro-4-fluoro-benzoic acid (11.75 g, 67.3 mmol) in EtOH was added PTSA (1.2 g) and the resulting mixture was heated under reflux for 2 days. On cooling the mixture was poured into water and the aqueous phase was basified with a solution of NaOH 1N. The product was extracted with CH₂Cl₂ and the organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to give the title compound as an oil (13.08g, 96%); [APCI MS] m/z 203 (MH⁺).

Intermediate 18: 3,4-difluoro-benzoic acid ethyl ester

3,4-Difluoro-benzoic acid (11 g, 69.57 mmol) was reacted as described for intermediate 1 to afford the title compound as an oil (11.78g, 91%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.84 (m, 2H), 7.22 (m, 1H), 4.37 (q, 2H), 1.38 (t, 3H).

Intermediate 19: 6-methyl-pyridine-2-carboxylic acid ethyl ester

6-Methyl-pyridine-2-carboxylic acid (25g, 182.3 mmol) was reacted as described for intermediate 1 to afford the title compound as an oil (22.9g, 76.13%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.95 (d, 1H), 7.75 (t, 1H), 7.35 (d, 1H), 4.5 (q, 2H), 2.7 (s, 3H), 1.45 (t, 3H).

Intermediate 20: 6-fluoro-pyridine-2-carboxylic acid

30 To a solution of 2-fluoro-6-methyl-pyridine (2.5g, 22.5 mmol) in water (170 ml) was added portionwise KMnO₄ (2g, 12.65 mmol) and the mixture was heated to reflux. Then KMnO₄ (8g, 50.63 mmol) was added portionwise and the mixture was heated

under reflux for 3 hours. On cooling, the precipitate was filtered and the filtrate was acidified with a solution of HCl and then concentrated under reduced pressure. The residue was triturated with hot EtOH, the solid was filtered and the filtrate was concentrated to dryness under reduced pressure. The title compound was obtained as a white solid (1.7g, 53%); m.p. 137°C.

Intermediate 21: 6-fluoro-pyridine-2-carboxylic acid isopropyl ester

Intermediate 20 (1g, 7.09 mmol) was added portionwise to thionyl chloride (3 ml) and the mixture was heated under reflux for 3 hours and then concentrated under reduced pressure. Isopropanol (3 ml) was added to the residue and the mixture was stirred at room temperature for 5 minutes and then concentrated under reduced pressure. The residue was treated with a saturated solution of NaHCO₃, extracted with ethyl acetate, the organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The title compound was obtained as a cream oil (1.2g, 93%); [APCI MS] m/z: 184 (MH+).

Intermediate 22: 1-methyl-4-hydroxymethyl-imidazole

To a suspension of 1-methyl-imidazole-4-carboxylic acid (11.4g, 90 mmol) in THF (500ml) at 0°C was added dropwise LiAlH₄ (solution 1M in THF, 117ml, 117 mmol) and the mixture was stirred at room temperature overnight and then at 50°C for 1 hour. On cooling, water (3 ml) was added followed by Na₂SO₄, and the resulting precipitate was filtered through a celite pad. The filtrate was concentrated under reduced pressure to afford the title compound as a solid (8g, 78.95%); ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.25 (s, 1H), 6.7 (s, 1H), 5.25 (m, 1H), 4.4 (s, 2H), 3.45 (s, 3H).

Intermediate 23: 1-methyl-4-chloromethyl-imidazole hydrochloride

To a solution of intermediate 22 (5g, 44.64 mmol) in CH₂Cl₂ (10 ml) at 0°C was added dropwise thionyl chloride (50 ml) and then the mixture was stirred at room temperature overnight and then at reflux for 3 hours. The mixture was concentrated under reduced pressure, and diethyl ether added. The resulting precipitate was filtered and dried to give the title product as a brown solid (4g, 53.81%); ¹H NMR (300 MHz, d⁶-DMSO) δ ppm: 9.25 (s, 1H), 7.8 (s, 1H), 4.95 (s, 2H), 3.9 (s, 3H).

Intermediate 24: 4-(morpholin-4-yl)-bromobenzene


To a solution of 4-phenylmorpholine (18g, 110.4 mmol) in ethanol (400ml) cooled in an iced bath, was added dropwise bromine (5.95 ml, 115.9 mmol) and the mixture

was stirred at room temperature for 2 hours. The mixture was poured into water and the solution was made basic by addition of a solution of sodium hydroxide (1N). The resulting precipitate was filtered, washed with water and dried. Crystallisation from diisopropyl ether gave the title compound as white crystals (15g, 56.13%); m.p. 126-128°C.

Intermediate 25: 1-ethyl-4-(4-bromophenyl)-piperazine


To a solution of 1-ethyl-4-phenylpiperazine (18g, 95mmol) in ethanol (600ml) cooled in an iced bath, was added dropwise bromine (5.1ml, 99mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was poured into water and made basic by addition of a solution of sodium hydroxide (1N). After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (9/1). The titled compound was obtained as a solid (21g, 82.4%); [APCI MS] $m/z = 270$ (MH^+).

Intermediate 26: 4-(2-(pyrrolidin-1-yl)-ethoxy)-iodobenzene



To a solution of 4-iodophenol (6g, 27.3mmol) in acetone (200ml) were added caesium carbonate (22.2g, 68.4 mmol) and N-(2-chloroethyl)-pyrrolidine hydrochloride (7g, 41 mmol) and the mixture was heated under reflux for 4 hours. On cooling, the mixture was poured into water, and extracted with CH_2Cl_2 . The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure to give the title compound as a red oil (8g, 92.53%); ^1H NMR (300MHz, CDCl_3 , ppm) δ : 7.5 (d, 2H), 6.65 (d, 2H), 4 (t, 2H), 2.8 (t, 2H), 2.55 (m, 4H), 1.75 (m, 4H).


Intermediate 27: N-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)-phenyl]-morpholine



To a solution of intermediate 24 (20g, 82.64 mmol) in dioxane (200ml) was added 4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (13.2 ml, 99.17 mmol), dichloro bis(triphenylphosphine) palladium(II) (3g, 4.13 mmol) and triethylamine (34.5 ml,


247.93 mmol) and the mixture was heated under reflux during 4 hours and then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (CH_2Cl_2) to give the title compound as an orange oil which crystallised (19.98 g, 83.94%); [APCI MS] m/z 289.07 (MH^+).

Intermediate 28: 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-piperazine




To a solution of intermediate 25 (3g, 11mmol) in dioxane (100ml) was added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.8ml, 12mmol), dichlorobis(triphenylphosphine)palladium(II) (0.392g, 0.57mmol) and triethylamine (4.65ml, 33mmol) and the mixture was heated under reflux for 12 hours. On cooling, the mixture was poured into water and extracted with CH_2Cl_2 . The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure to give a residue which was purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (90:10). The titled compound was obtained as a brown oil which crystallised on standing (2g, 55.48%); m.p. 130-134°C.

Intermediate 29: 1-[2-(pyrrolidin-1-yl)-ethoxy]-4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-benzene



Intermediate 26 (8g, 25.24mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4ml, 27.6mmol) were reacted as described for intermediate 27 to afford the titled compound as a solid (8g, 99.99%); m.p. 160-164°C.


Intermediate 30: 1-[aminocarbonylmethoxy]-4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-benzene



To a solution of 4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-phenol (5g, 22.7mmol) in acetone (80ml) were added cesium carbonate (10.37g, 32 mmol) and bromoacetamide (4.39g, 32 mmol) and the mixture was heated at 70°C for 3 hours.


- 5 On cooling, the mixture was concentrated under reduced pressure and the residue was treated with water and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄, and concentrated. After trituration with diisopropyl ether, the title compound was obtained as a solid (4g, 63.54%); m.p. 166-168°C.

- 10 Intermediate 31: 1-[(1-methyl-imidazol-4-yl)-methoxy]-4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-benzene



- 4-[4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl]phenol (1g, 4.54 mmol) and intermediate 22 (1.88g, 11.4 mmol) were reacted as described for intermediate 29, to afford, after chromatography on silica gel (CH₂Cl₂/MeOH, 95/5), the title compound as a pale yellow oil (0.5g, 35%); ¹H NMR (300MHz, CDCl₃, ppm) δ :7.6 (d, 2H), 7.3 (s, 1H), 6.8 (m, 3H), 4.9 (s, 2H), 3.5 (s, 3H), 1.2 (s, 12H).


- 20 Intermediate 32: 1-[(morpholin-4-yl)carbonylmethoxy]-4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-benzene



- To a solution of 4-[4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl]-phenol (6.6g, 30mmol) in CH₃CN were added potassium carbonate (12.42g, 90 mmol) and N-(chloroacetyl)-morpholine (4.89g, 30 mmol) and the mixture was heated under reflux for 3 hours. On cooling the mixture was concentrated under reduced pressure, and


the residue was treated with water and extracted with EtOAc. The organic phase was dried over Na₂SO₄ and concentrated. Trituration from hexane gave the title compound as a grey solid (9.5g, 91%); m.p. 112°C; [APCI MS] m/z 348 (MH⁺).

5 Intermediate 33: 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(tetrahydro-pyran-4-yl)-benzamide




- 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid (70.16g, 0.28 mol) was treated with SOCl₂ (2 vol.) and the reaction mixture was stirred to reflux for 2 hours.
- 10 After evaporation, the residue was diluted in toluene and poured into a solution at 10°C of tetrahydro-pyran-4-ylamine (34.34g, 0.339) and triethylamine (79 mL, 0.57 mol) in CH₂Cl₂. The reaction mixture was stirred at room temperature during 2 days and water (490 mL) was added to give a precipitate which was filtered off and washed with EtOAc. After purification by flash chromatography using CH₂Cl₂/MeOH
- 15 (95:5). The title compound was obtained as a solid (17.02g, 18%); ¹H NMR (400 MHz, CDCl₃, ppm) δ : 7.85 (d, 2H), 7.72 (d, 2H), 5.98 (m, 1H), 4.20 (s, 1H), 3.99 (m, 2H), 3.35 (t, 2H), 2.01 (d, 2H), 1.57 (m, 2H), 1.35 (s, 12H).

20 Intermediate 34 : N-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanesulfonamide




- To a solution of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-aniline (Aldrich, 5g, 22.8 mmol) in CH₂Cl₂ (20ml) was added NaHCO₃ (2.3g, 27.4 mmol) and methanesulfonyl chloride (13.2 mL, 171 mmol) and the reaction mixture was stirred
- 25 at room temperature during 6 days. Water was added and the product was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, and concentrated under reduced pressure. Crystallisation from diethyl ether gave the title compound as a white powder (2.52g, 37%); ¹H NMR (300 MHz, CDCl₃, ppm) δ : 7.78 (d, 2H), 7.18 (d, 2H), 6.69 (m, 1H), 3.02 (s, 3H), 1.33 (s, 12H).

Intermediate 35: N-[(4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl)carbonyl]-morpholine



- 5 To a solution of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid (5g, 20.15 mmol) in $\text{CH}_2\text{Cl}_2/\text{DMF}$ (50ml/5ml) were added morpholine (2.1ml, 24.2mmol), HOBT (3.3g, 24.2mmol), EDCI (4.65g, 24.2mmol) and triethylamine (4.2ml, 30.2mmol) and the reaction mixture was stirred at room temperature during 3 days. Water was added and the product was extracted with CH_2Cl_2 . The organic phase
- 10 was dried over Na_2SO_4 and concentrated under reduced pressure. Trituration with diisopropyl ether gave the title compound as a white solid (4.21g, 66%); ^1H NMR (300 MHz, CDCl_3 , ppm) δ : 7.8 (d, 2H), 7.4 (d, 2H), 3.7 (m, 4H), 3.55 (m, 2H), 3.35 (m, 2H), 1.3 (s, 12H).

15 Intermediate 36: 1-ethyl-4-[(4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl)carbonyl]-piperazine



- 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid (8.24g, 33.22 mmol) and N-ethylpiperazine (5.1ml, 39.87mmol) were reacted as described for
- 20 intermediate 34 to afford, after chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 95/5), the title compound as a pale yellow oil which crystallised (9.64g, 84%); [APCI MS] m/z 345 (MH^+).


Intermediate 37 : 2-(4-bromophenyl)-4-methyl-pyridine

- 25 2-Bromo-4-methylpyridine (10 g, 58.14 mmol) was dissolved in toluene (100 ml) and tetrakis(triphenylphosphine)palladium(0) (5 mol%, 3.36 g) added under N_2 and degassed. Aqueous sodium carbonate (2M, 2 eq) was added slowly and stirred for 10min. A solution of 4-bromophenylboronic acid (Lancaster, 14 g, 1.2 eq) in ethanol (20 ml) was added dropwise and the mixture was heated under reflux overnight and

then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The resulting residue was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{cyclohexane}$ 6/4 then 8/2 then CH_2Cl_2). After crystallisation from pentane, the titled compound was obtained as

5 white crystals (6.3g, 43.7%); ^1H NMR (300MHz, CDCl_3 , ppm) δ 8.5 (d, 1H), 7.83 (d, 2H), 7.56 (d, 2H), 7.5 (s, 1H), 7.05 (m, 1H), 2.4 (s, 3H).


Intermediate 38: 2-[4-(morpholin-4-yl)phenyl]-4-methyl-pyridine



10 To a solution of intermediate 37 (2.66 g, 10.72 mmol) in toluene (50 ml) was added morpholine (1.12 ml, 1.2 eq, 12.9 mmol), $\text{Pd}_2(\text{dba}_2)_3$ (0.49g, 0.05 eq, 0.53 mmol), binap (1g, 0.15 eq, 1.6 mmol) and potassium tert-butoxide (1.44g, 1.4 eq, 15 mmol) and the mixture was heated under reflux for 2 h and then poured into water. After

15 extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The resulting residue was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ gradient from 99 :1 to 95 :5). The title compound was obtained as a yellow solid (2.6g, 95.43%); ^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.5 (d, 1H), 7.95 (d, 2H), 7.5 (s, 1H), 7 (m, 3H), 3.9 (m, 4H), 3.3 (m, 4H), 2.4 (s, 3H).

20 Intermediate 39 : 2-[2-bromo-pyridin-4-yl]-1-pyridin-2-yl-ethanone




To a solution of 2-bromo-4-methyl-pyridine (27 g, 157 mmol) in dry THF (270 ml) was added ethyl picolinate (28.5 g, 188.7 mmol). The resulting mixture was cooled to -78°C under argon and a solution of sodium bis(trimethylsilyl)amide 1M in THF (345

25 ml, 345 mmol) was added dropwise at -78°C . The resulting reaction mixture was allowed to reach room temperature and subsequently stirred overnight. The solvent was evaporated under reduced pressure and the solid residue triturated with diethyl ether, filtered and washed with diethyl ether. The solid was then diluted with saturated NH_4Cl solution and the aqueous phase extracted with EtOAc. The organic

30 layer was dried over sodium sulfate and concentrated. The resulting orange powder

was washed with pentane to give the title compound as a yellow solid (33.97 g); m.p. 111.2°C.


Intermediate 40 : 2-[2-bromo-pyridin-4-yl]-1-(6-methyl-pyridin-2-yl)-ethanone



- 5 To a solution of 2-bromo-4-methyl-pyridine (5 g, 29mmol) in dry THF (70 ml), a solution of sodium bis-(trimethylsilyl)amide 2M in THF (32 ml, 64 mmol) was added dropwise at -30°C under nitrogen. The mixture was stirred at -30°C for 1h, then intermediate 19 (4.82 g, 32.3mmol, 1.1eq) was added. The reaction mixture was stirred at room temperature overnight. Diethyl ether was added and the precipitated
10 solid was filtered and washed with diethyl ether. The solid was then diluted with saturated NH₄Cl solution and the aqueous phase was extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and concentrated. The resulting orange powder was washed with pentane to give the title compound as a yellow solid (5.84 g, 70%). [APCI MS] m/z, 292 (MH⁺).


15

Intermediate 41 : 2-(2-bromo-pyridin-4-yl)-1-(3-chloro-4-fluoro-phenyl)-ethanone




- 2-Bromo-4-methyl-pyridine (9.2g, 53.5 mmol) and intermediate 17 (13 g, 64.2 mmol) were reacted as described for intermediate 39 to afford the title compound as
20 an orange solid (17.16 g, 98%); [APCI MS] m/z: 330 (MH⁺).

Intermediate 42: 2-(2-bromo-pyridin-4-yl)-1-(3,4-difluoro-phenyl)-ethanone




2-Bromo-4-methyl-pyridine (9.056g, 52.64 mmol) and intermediate 18 (11.75 g, 63.17 mmol) were reacted as described for intermediate 39 to afford the title compound as an ocre solid (14.54 g, 88.5%); [APCI MS] m/z: 314 (MH⁺).

5 Intermediate 43 : 2-(2-bromo-pyridin-4-yl)-1-(3-chloro-phenyl)-ethanone




2-Bromo-4-methyl-pyridine (7.75g, 45.1 mmol) and methyl-3-chlorobenzoate (10 g, 58.6 mmol) were reacted as described for intermediate 39 to afford the title compound as an orange powder (13.02 g, 93%); ¹H NMR (300 MHz, CDCl₃, ppm) δ: 8.34 (d, 1H), 7.95 (m, 1H), 7.84 (d, 1H), 7.59 (d, 1H), 7.46 (d, 1H), 7.41 (d, 1H), 7.13 (d, 1H), 4.24 (s, 2H).

Intermediate 44 : 2-(2-bromo-pyridin-4-yl)-1-(6-fluoro-pyridin-2-yl)-ethanone



15 To a solution of 2-bromo-4-methyl-pyridine (2.58g, 15 mmol) in anhydrous THF (50 ml) at -30°C, was added dropwise NaHMDS (solution 2M in THF, 15ml, 30 mmol) and the mixture was stirred at -30°C for 2 hours. A solution of intermediate 20 (2.74g, 15 mmol) in THF (50 ml) was added dropwise and the mixture was stirred at -30°C for 1 hour and then poured into water. After extraction with EtOAc, the organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (CH₂Cl₂/MeOH, 99 :1). The title compound was obtained as a yellow solid (1.6g, 36%) ; [APCI MS] m/z=295 (MH⁺).


Intermediate 45 : 2-[2-(4-(morpholin-4-yl)phenyl)-pyridin-4-yl]-1-pyridin-2-yl-ethanone



To a solution of Intermediate 38 (2.6 g, 10.24 mmol) in dry THF (100 ml) under argon, was added dropwise a solution of sodium bis-(trimethylsilyl)amide 1M in THF (22.52 ml, 2.2 eq, 22.53 mmol). The solution was stirred room temperature for 0.5h, then a solution of ethyl picolinate (1.66 ml, 1.2 eq, 12.3 mmol) in dry THF (20 ml) was added dropwise and the reaction mixture stirred at room temperature for 4 h. The solvent was evaporated under reduced pressure and the solid precipitated with diisopropyl ether. The brown solid was then taken up in saturated NH_4Cl solution and the aqueous phase extracted with CH_2Cl_2 . The organic layer was dried over sodium sulfate and concentrated under reduced pressure to leave a residue which was purified by chromatography on silica gel (CH_2Cl_2 then $\text{CH}_2\text{Cl}_2/\text{MeOH}$ gradient from 99 :1 to 97 :3). The title compound was obtained as an orange oil (1.42 g, 38.64%) ; ^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.7 (d, 1H), 8.55 (d, 1H), 8.05 (d, 1H), 7.9 (d, 2H), 7.8 (m, 1H), 7.5 (m, 1H), 7.15 (m, 1H), 6.95 (m, 3H), 4.55 (s, 2H), 3.85 (m, 4H), 3.2 (m, 4H).

15

Intermediate 46 : 2-[2-(4-(methanesulfonyl)phenyl)-pyridin-4-yl]-1-(6-methylpyridin-2-yl)-ethanone



To a solution of intermediate 40 (2g, 6.87mmol) in DME (80ml) was added 4-(methanesulfonyl)-phenyl boronic acid (2.1g, 10.31mmol), tetrakis(triphenylphosphine) palladium(0) (0.4g, 0.35mmol) and Na_2CO_3 (solution 2M, 22ml) and the mixture was heated under reflux overnight and then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95 :5). The title compound was obtained as a yellow oil (1.1g, 43.73%); [APCI MS] $m/z=367$ (MH^+).

The following compounds of formula (IIa) were prepared by methods analogous to that described for intermediate 46 using the appropriate boronic acid derivative (see Table 2).

57





Table 2

Int.	R ¹	Physical data
47	4-ethylpiperazin-1-yl	APCI MS m/z 387 (MH ⁺)
48	morpholin-4-yl	APCI MS m/z 374 (MH ⁺)
49	methoxycarbonyl	APCI MS m/z 347 (MH ⁺)
50	formyl	APCI MS m/z 317 (MH ⁺)
51	methoxy	APCI MS m/z 319 (MH ⁺)
52	trifluoromethoxy	m.p. 76-78°C
53	2-(pyrrolidin-1-yl)ethoxy	APCI MS m/z 402 (MH ⁺)
54	aminocarbonylmethoxy	m.p. 144-146°C
55	(1-methyl-imidazol-4-yl)methoxy	APCI MS m/z 399 (MH ⁺)


Intermediate 56: 2-[2-(4-(carboxy)-phenyl)-pyridin-4-yl]-1-(6-methylpyridin-2-yl)-ethanone

5 ethanone



To a solution of intermediate 49 (1.2g, 3.47mmol) in MeOH (100ml) was added sodium hydroxide (solution 1N, 5ml, 5.2mmol) and the mixture was heated under reflux for 48 hours. After cooling, a solution of HCl 1N (5 ml) was added and the precipitate was filtered and dried. The title compound was obtained as an orange solid (0.8g, 69.5%); [APCI MS] m/z= 333 (MH⁺).

Intermediate 57: 2-[2-(4-((morpholin-4-yl)carbonyl)-phenyl)-pyridin-4-yl]-1-(6-methylpyridin-2-yl)-ethanone




15

To a solution of intermediate 56 (0.8g, 2.41 mmol) in CH₂Cl₂ (50ml) were added morpholine (0.32ml, 3.61mmol), HOBT (0.49g, 3.61 mmol), EDCI (0.63g, 3.61 mmol), triethylamine (0.84ml, 6 mmol) and the mixture was stirred at room


temperature for 24 hours and then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (9 : 1). The title compound was obtained as an orange oil (0.8g, 85.35%); [APCI MS] $m/z = 390$ (MH^+).

Intermediate 58: 2-[2-[4-((tetrahydropyran-4-yl)-aminocarbonyl)-phenyl]pyridin-4-yl]-1-(6-methylpyridin-2-yl)-ethanone




Intermediate 56 (1g, 3mmol) and 4-amino-tetrahydropyran (340mg, 3.3mmol) were reacted as described for intermediate 56 to afford, after chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9/1), the title compound as a yellow oil (0.3g, 24%); ^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.58 (d, 1H), 7.98 (m, 2H), 7.8 (m, 3H), 7.66 (m, 2H), 7.29 (m, 1H), 7.19 (m, 1H), 6.01 (m, 1H), 4.57 (s, 2H), 4.15 (m, 1H), 3.93 (m, 2H), 3.48 (m, 2H), 2.6 (s, 3H), 1.95 (m, 2H), 1.55 (m, 2H).

Intermediate 59: 2-[2-(4-((morpholin-4-yl)methyl)-phenyl)-pyridin-4-yl]-1-(6-methylpyridin-2-yl)-ethanone




To a solution of intermediate 50 (1g, 3.2mmol) in CH_2Cl_2 (100ml) were added morpholine (0.36g, 4.1mmol) and sodium triacetoxyborohydride (0.88g, 4.1mmol) and the mixture was stirred at room temperature for 3 hours and then poured into a saturated solution of NaHCO_3 . After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The titled compound was obtained as a yellow oil (1.1g, 89.82%); [APCI MS] $m/z = 388$ (MH^+).

Intermediate 60: [(2-(4-ethanesulfonylphenyl)-pyridin-4-yl)-(phenylamino)-methyl]-phosphonic acid diphenylester



To a solution of 2-chloro-pyridine-4-carboxaldehyde (1g, 7.06mmol) in DME (50ml)
5 was added 4-(ethanesulfonyl)phenyl boronic acid (1.97g, 9.18 mmol),
tetrakis(triphenylphosphine) palladium(0) (0.816g, 0.7mmol) and Na₂CO₃ (solution
2M, 7ml) and the mixture was heated under reflux overnight and then poured into
water. After extraction with CH₂Cl₂, the organic phase was dried over Na₂SO₄, and
concentrated under reduced pressure. The residue was purified by chromatography
10 on silica gel eluting with CH₂Cl₂/MeOH (99/1) to afford 2-(4-ethanesulfonylphenyl)-
pyridine-4-carboxaldehyde as a yellow oil (1.94g, 98%). To a solution of 2-(4-
ethanesulfonylphenyl)-pyridine-4-carboxaldehyde (1.94g, 7.06 mmol) in iPrOH were
added aniline (0.772ml, 8.47 mmol) and diphenylphosphite (1.91ml, 9.9 mmol) and
the mixture was stirred at room temperature for 18 hours and then concentrated
15 under reduced pressure. The residue was treated with water and extracted with
CH₂Cl₂, the organic phase was dried over Na₂SO₄ and concentrated. After
chromatography on silica gel (CH₂Cl₂), the title compound was obtained as a yellow
oil (1.45g, 35.13%); [APCI MS] m/z 585 (MH⁺).

20 Intermediate 61: 1-[2-(4-ethanesulfonylphenyl)-pyridin-4-yl]-2-[6-methyl-pyridin-2-yl]-ethanone




To a solution of intermediate 60 (1.45g, 2.48 mmol) in THF/iPrOH were added 6-
methyl-pyridine-2-carboxaldehyde (0.251g, 2.07 mmol) and cesium carbonate
25 (1.35g, 4.14 mmol) and the mixture was stirred at room temperature for 18 hours and
then neutralised with a solution of NaHCO₃. After concentration under reduced
pressure, the residue was treated with water and extracted with CH₂Cl₂. The organic
phase was dried over Na₂SO₄ and concentrated under reduced pressure. After

chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 99 :1), the title compound was obtained as a yellow oil (0.321g; 34.02%); [APCI MS] m/z 381 (MH^+).


Intermediate 62: 2-bromo-N-methoxy-N-methyl-4-pyridinecarboxamide

5



To a suspension of 2-bromo-4-pyridinecarboxylic acid (23.5g, 116mmol) in CH_2Cl_2 (600mL) were added under nitrogen HOBT (17.3g, 128mmol), EDCI (24.5g, 128mmol), triethylamine (46.85g, 464mmol) and N,O-dimethylhydroxylamine hydrochloride (17.02g, 175mmol). The reaction mixture was stirred at room temperature for 3 hours and then partitioned between water and CH_2Cl_2 . The organic phase was dried over Na_2SO_4 , filtered and evaporated under reduced pressure to afford the title compound as a white solid (17g, 59.64 %); [APCI MS] m/z 246 (MH^+).


15 Intermediate 63: 1-[2-bromo-pyridin-4-yl]-2-[pyridin-2-yl]-ethanone



To a solution of 6-methylpyridine (2.79g; 30 mmol) in dry THF (20ml) under nitrogen cooled at -80°C , was added dropwise NaHMDS (solution 1M/THF, 36 ml, 36 mmol). and the mixture was stirred for 1hour at -80°C . A solution of intermediate 62 (7.35g; 30 mmol) in dry THF (10mL) was added dropwise and the mixture was then stirred at room temperature overnight and then concentrated under reduced pressure. The residue was treated with hexane and the resulting precipitate was filtered. The solid was then diluted with saturated NH_4Cl solution and the aqueous phase extracted with EtOAc. The organic layer was dried over sodium sulfate and concentrated. After chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 98 :2), the title compound was obtained as a yellow solid (4.1g, 49.34%); m.p. 96°C .

Intermediate 63: 1-[2-bromo-pyridin-4-yl]-2-[6-methyl-pyridin-2-yl]-ethanone

61



To a solution of 2,6-lutidine (4.28g; 40mmol) was dissolved in dry THF (100mL) under nitrogen and the solution was cooled to -30°C. 2.5M n-Butyllithium in hexanes (16mL; 40mmol) was added at -30°C, then the mixture was stirred 1.5h at ambient temperature before being cooled to -30 to -40°C. A solution of intermediate 62 (4.9g; 20mmol) in dry THF (20mL) was added at -40°C and the reaction stirred for 2h. Saturated aqueous ammonium chloride was added and the mixture was extracted with EtOAc. The organic phase was dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by chromatography on silica gel 60 (CH₂Cl₂/ MeOH, 99/1) to give the title compound (3.42g; 58%) as a yellow solid; m.p. 126°C; [MS APCI] m/z : 292 (MH⁺).

The following compounds of formula (III Ea) were prepared by methods analogous to that described for intermediate 46 using the starting materials indicated (see Table 3).





Table 3


Int.	R ¹	R ²	From Int.	Physical data
65	(tetrahydropyran-4-yl)aminocarbonyl	H	63 + 33	APCI MS m/z 402 (MH ⁺)
66	morpholin-4-yl	H	63 + 27	APCI MS m/z 360 (MH ⁺)
67	chloro	CH ₃	64	APCI MS m/z 323 (MH ⁺)
68	trifluoromethoxy	CH ₃	64	APCI MS m/z 373 (MH ⁺)
69	(morpholin-4-yl)carbonyl	CH ₃	64 + 35	APCI MS m/z 402 (MH ⁺)
70	(4-ethylpiperazin-1-yl)carbonyl	CH ₃	64 + 36	APCI MS m/z 429 (MH ⁺)
71	(tetrahydropyran-4-yl)aminocarbonyl	CH ₃	64 + 33	APCI MS m/z 416 (MH ⁺)
72	morpholin-4-yl	CH ₃	64 + 27	APCI MS m/z 374 (MH ⁺)
73	2-(pyrolidin-1-yl)ethoxy	CH ₃	64 + 29	APCI MS m/z 402 (MH ⁺)
74	aminocarbonylmethoxy	CH ₃	64 + 30	APCI MS m/z 362 (MH ⁺)
75	(morpholin-4-yl)carbonylmethoxy	CH ₃	64 + 32	APCI MS m/z 432 (MH ⁺)
76	formyl	CH ₃	64	APCI MS m/z 317 (MH ⁺)

Intermediate 77: 2-(6-methylpyridin-2-yl)-1-[2-(4-((morpholin-4-yl)methyl)-phenyl)-pyridin-4-yl]-ethanone




- 5 To a solution of intermediate 76 (0.984g, 3 mmol) in 1,2-dichloroethane (40 ml) were added morpholine (0.34g, 3.9 mmol), sodium triacetoxyborohydride (0.826g, 3.9 mmol) and acetic acid (0.216g, 3.6 mmol) and the mixture was stirred at room temperature for 3 hours and then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure.
- 10 The title compound was obtained as an oil (1.1g, 91%); [APCI MS] m/z 388 (MH^+).

Intermediate 78: 2-(6-methylpyridin-2-yl)-1-[2-(4-((pyrrolidin-1-yl)methyl)-phenyl)-pyridin-4-yl]-ethanone



- 15 Intermediate 76 (0.7g, 2.2 mmol) and pyrrolidine (0.203g, 2.8 mmol) were reacted as described for intermediate 76, to afford after chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9 :1), the title compound as a yellow gum (0.5g, 60.84%); [APCI MS] m/z 372 (MH^+).


20 Intermediate 79: 2-(6-methylpyridin-2-yl)-1-[2-(4-((dimethylamino)methyl)-phenyl)-pyridin-4-yl]-ethanone



Intermediate 76 (0.7g, 2.2 mmol) and dimethylamine (solution 2M in THF, 1.4ml, 2.86 mmol) were reacted as described for intermediate 76, to afford after chromatography

on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9 : 1), the title compound as a yellow gum (0.4g, 52.34%); [APCI MS] m/z 346 (MH^+).

Intermediate 80: 2-Bromo-4-(3-(6-methyl-pyridin-2-yl)-1H-pyrazol-4-yl)pyridine




5

A solution of intermediate 40 (5.84 g, 20 mmol) in dry DMF (20 ml) under nitrogen was treated with glacial acetic acid (2.4eq, 2.76 ml) over 2 min. DMF.DMA (1.5eq., 4 ml) was added dropwise and the mixture stirred at room temperature under nitrogen for 1 hour. Hydrazine monohydrate (7.5eq, 91 ml, 1.876 mol) was added dropwise at room temperature and the resulting mixture heated at 50°C for 3 hours. The reaction mixture was poured into water (300ml) and extracted with CH_2Cl_2 . The organic phases were combined, dried over Na_2SO_4 and filtered. The solvent was evaporated under reduced pressure to afford a brown oil which after purification by chromatography on silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98:2) gave the title compound as a yellow solid (3.07 g, 49%); [APCI MS] m/z 315 (MH^+).

15


Intermediate 81: 2-bromo-4-[5-methyl-3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridine



Intermediate 40 (2 g, 6.9mmol) was reacted with N,N-dimethylacetamide dimethylacetal (1.38g, 10mmol) as described for intermediate 80 to afford the title compound as a brown solid (0.9g, %); [APCI MS] m/z 328 (MH^+).

20

Intermediate 82: 2-bromo-4-[3-(6-methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridine




yl]pyridine

25


Intermediate 80 (3.07 g, 9.8 mmol) and trityl chloride (1.5 eq, 4.1 g, 14.7 mmol) were reacted with potassium carbonate (3eq, 29.4mmol) in acetone (100ml). The reaction mixture was subsequently heated to reflux and stirred for 24 hours. The reaction mixture was filtered, the filtrate concentrated and then partitioned between CH₂Cl₂ and H₂O. The organic phase was dried over Na₂SO₄ and concentrated. The resulting crude material was purified by flash chromatography on silica gel, eluting with CH₂Cl₂/MeOH (98:2) to give the title compound as the major isomer of a mixture of the two isomers, as a light yellow solid (4.9 g, 90%); [APCI MS] m/z: 558 (MH⁺).

10 Intermediate 83: 2-bromo-4-[5-methyl-3-(6-methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridine



Intermediate 81 (0.9 g, 2.74mmol) and trityl chloride (0.84 g, 3 mmol) were reacted as described for intermediate 82 to afford the title compound as a mixture of the two isomers, as a white powder (1.5 g, 95.87%); [APCI MS] m/z 329 (MH⁺ loss of trityl).









Intermediate 84: 3-(2-bromo-pyridin-4-yl)-2-(pyridin-2-yl)-imidazo[1,2-a]pyridine




To a solution of intermediate 39 (5g, 18.05mmol) in CH₂Cl₂ (30 ml) was added bromine-polymer-supported (11.28g, 18.05 mmol) and the suspension was stirred at room temperature for 5 hours. The resin was removed by filtration, with the filtrate being added directly to 2-amino-pyridine (3.4 g, 36.06 mmol) and the resin washed many times with ethanol. The filtrate was heated under reflux for 18 hours, allowed to cool and then concentrated. The residue was treated with water and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄ and evaporated under reduced pressure to give a crude solid which was precipitated from diisopropyl ether to afford the title compound as a brown powder (3.05g; 48%); m.p. 227°C.

The following intermediates (see Table 4) were prepared by methods analogous to that described for intermediate 84 from the starting materials indicated.

Table 4


Int.	structures	From int.	Physical data
85		40	^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.47 (d, 1H), 8.12 (d, 1H), 7.8 (m, 2H), 7.7 (d, 1H), 7.6 (t, 1H), 7.47 (d, 1H), 7.29 (t, 1H), 7.05 (d, 1H), 6.85 (t, 1H), 2.39 (s, 3H)
86		41	APCI MS m/z 404 (MH^+)
87		42	APCI MS m/z 386 (MH^+)
88		40	^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.5 (d, 1H), 8.09 (d, 1H), 7.82 (s, 2H), 7.65 (t, 2H), 7.45 (d, 1H), 7.27 (d, 1H), 7.08 (d, 1H), 2.39 (s, 3H)
89		40	^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.43 (d, 1H), 8.00 (d, 1H), 7.82 (s, 1H), 7.78 (d, 1H), 7.60 (t, 1H), 7.44 (m, 2H), 7.05 (d, 1H), 6.70 (d, 1H), 2.43 (s, 3H), 2.40 (s, 3H)
90		40	^1H NMR (300MHz, CDCl_3 , ppm) δ : 8.55 (d, 1H), 8 (d, 1H), 7.85 (d, 1H), 7.8 (s, 1H), 7.65 (t, 1H), 7.45 (d, 1H), 7.1 (m, 2H), 6.8 (t, 1H), 2.7 (s, 3H), 2.4 (s, 3H)
91		43	APCI MS m/z 384 (MH^+)
92		44	APCI MS m/z 369 (MH^+)

Intermediate 93: 4-{4-[3-(6-Methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridin-2-yl}-phenol




- To a solution of intermediate 82 (2 g, 3.6 mmol) in a mixture of DME (36 ml) and water (18 ml) were added tetrakis-triphenylphosphine palladium (0.2 g), Na_2CO_3 (0.99g) and 4-hydroxyphenyl boronic acid, pinacol ester (1.4 eq, 1.15 g, 4.32 mmol) and the resulting mixture was heated under reflux overnight. The cooled mixture was poured into water and extracted with CH_2Cl_2 . The organic phase was washed with water, dried over Na_2SO_4 and filtered. Evaporation of the solvent in vacuo gave a crude oil which was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5) to give the title compound as a white solid (1.7 g, 83%), which contained the 2-trityl isomer as a minor component; [APCI MS] m/z 571 (MH^+).

Intermediate 94: 4-{4-[3-(6-Methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridin-2-yl}-benzoic acid




- Intermediate 82 (1g, 1.8mmol) and 4-carboxybenzene boronic acid (0.36g, 2.52mmol) were coupled and treated as described for intermediate 93 to afford the title compound as a white solid (600mg, 61%) containing the 2-trityl isomer as a minor component; [APCI MS] m/z 599 (MH^+).

- Intermediate 95: 4-{4-[3-(6-methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridin-2-yl}benzaldehyde




- Intermediate 82 (1g, 1.8mmol) and 4-formylphenylboronic acid (0.35g, 2.3mmol) were coupled and treated as described for intermediate 93 to afford the title compound as a grey solid (1g; 96%) containing the 2-trityl isomer as a minor component; [APCI MS] m/z 583 (MH^+).

Intermediate 96: 2-(4-bromophenyl)-4-[3-(6-methylpyridin-2-yl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]pyridine




- 5 Intermediate 82 (2g, 3.6mmol) and 4-bromophenylboronic acid (0.755g, 3.78mmol) were coupled and treated as described for intermediate 93 to afford the title compound as a white solid (2.1g, 92%) containing the 2-trityl isomer as a minor component; [APCI MS] m/z 633/635 (MH^+).

- 10 Intermediate 97: (4-{4-[3-(6-methylpyridin-2-yl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-pyridin-2-yl}phenyl)amine



- Intermediate 82 (1g, 1.8mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.512g, 2.3mmol) were coupled and treated as described for intermediate 93 to afford the title compound as a yellow solid (1g, 98%) containing the 2-trityl isomer as a minor component; [APCI MS] m/z 570 (MH^+).
- 15

Intermediate 98: 4-{4-[5-methyl-3-(6-methylpyridin-2-yl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl}benzaldehyde




20

Intermediate 83 (1.5g, 2.62mmol) and 4-formylphenylboronic acid (0.48g, 3.2mmol) were coupled and treated as described for intermediate 93 to afford the title compound as a yellow oil (1.6g, quantitative) containing the 2-trityl isomer as a minor component; [APCI MS] m/z 355 (MH^+ , loss of trityl).

25

Intermediate 99: 3-(2-(4-formyl-phenyl)-pyridin-4-yl)-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridine













A solution of intermediate 85 (500mg, 1.37 mmol) in DME (50 mL) was treated with tetrakis (triphenylphosphine)palladium(0) (158 mg, 10%mol) and stirred at room temperature for 30 min. Na₂CO₃ (2M) (4.2 ml) was added to the reaction mixture, followed by 4-formylphenyl boronic acid (267mg, 1.78 mmol). The resulting mixture was heated under reflux overnight. The cooled mixture was poured into ice and extracted with CH₂Cl₂. The organic phase was washed with water, dried over Na₂SO₄ and filtered. Evaporation of the solvent in vacuo gave a crude oil which was purified by chromatography on silica gel (CH₂Cl₂/MeOH 95:5). The title compound was obtained as a cream powder (310 mg, 58%); ¹H NMR (300 MHz, CDCl₃, ppm) δ: 10.08 (s, 1H); 8.86 (d, 1H); 8.10-8.20 (m, 4H); 7.98 (d, 1H); 7.83 (d, 1H); 7.75 (d, 1H); 7.61 (t, 1H); 7.51 (m, 1H); 7.30 (t, 1H); 7.04 (d, 1H); 6.85(t, 1H); 2.31 (s, 3H).


The following intermediates (see Table 5) were prepared by methods analogous to that described for intermediate 99.

Table 5

Int.	structures	From int.	Physical data
100		84	APCI MS m/z 377 (MH ⁺)
101		86	APCI MS m/z 428 (MH ⁺)
102		87	APCI MS m/z 412 (MH ⁺)

Int.	structures	From int.	Physical data
103		88	APCI MS m/z 425 (MH ⁺)
104		89	APCI MS m/z 405 (MH ⁺)
105		90	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 10.1 (s, 1H), 8.9 (d, 1H), 8.2 (d, 2H), 8.15 (s, 1H), 8.1 (d, 1H), 8 (d, 2H), 7.85 (d, 1H), 7.6 (m, 2H), 7.1 (m, 2H), 6.8 (t, 1H), 2.8 (s, 3H), 2.4 (s, 3H)
106		85	APCI MS m/z 407 (MH ⁺)
107		84	APCI MS m/z 365 (MH ⁺)
108		85	APCI MS m/z 379 (MH ⁺)
109		91	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 9.05 (s, 1H), 8.55 (d, 1H), 7.95 (d, 1H), 7.6 (m, 3H), 7.5 (m, 2H), 7.25 (m, 1H), 7.1 (m, 4H), 6.7 (m, 3H)
110		90	APCI MS m/z 393 (MH ⁺)
111		89	APCI MS m/z 393 (MH ⁺)
112		84	APCI MS m/z 428 (MH ⁺)

Intermediate 113 : 3-[2-[4-(2-bromo-ethoxy)-phenyl]-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-a]pyridine



To a solution of intermediate 107 (0.38 g, 1.04 mmol) in acetone (20 ml) was added cesium carbonate (0.68 g, 2.08 mmol) and 1,2-dibromoethane (0.9 ml, 10.4 mmol) and the mixture was heated under reflux for 2 days. After cooling, the reaction was filtered and the solvent was removed in vacuo. After purification by chromatography on silica gel (CH₂Cl₂/MeOH, 90:10), the title compound was obtained as a yellow gum (140 mg, 28%); ¹H NMR (CDCl₃, 300 MHz) δ ppm: 8.78 (d, 1H), 8.49 (d, 1H), 8.14 (d, 1H), 7.93 (m, 4H), 7.72 (t, 2H), 7.34 (m, 2H), 7.17 (m, 1H), 7.00 (d, 2H), 6.83 (t, 1H), 4.33 (t, 2H), 3.65 (t, 3H).


The following intermediates (see Table 6) were prepared by methods analogous to that described for intermediate 113.

Table 6

Int.	structures	From int.	Physical data
114		108	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.75 (d, 1H), 8.15 (d, 1H), 7.93 (m, 3H), 7.71 (t, 2H), 7.56 (t, 2H), 7.35 (d, 1H), 7.26 (m, 1H), 7.00 (m, 3H), 6.82 (t, 1H), 4.33 (t, 2H), 3.65 (t, 2H), 2.37 (s, 3H)
115		109	APCI MS m/z 505 (MH ⁺)
116		111	APCI MS m/z 500 (MH ⁺)
117		110	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.75 (d, 1H), 8.05 (d, 1H), 7.95 (s, 1H), 7.9 (d, 1H), 7.7 (d, 1H), 7.55 (t, 1H), 7.35 (d, 1H), 7 (m, 2H), 6.9 (d, 2H), 6.75 (t, 1H), 4.35 (t, 2H), 3.65 (t,


Int.	structures	From int.	Physical data
			2H), 2.75 (s, 3H), 2.35 (s, 3H)

Intermediate 118: 2-Hydroximino-2-[2-Bromo-pyridin-4-yl]-1-(6-methyl-pyridin-2-yl)-ethan-1-one



- 5 A solution of intermediate 40 (20g, 68.7mmol) in aqueous HCl 18% (360ml) was cooled to 0°C using a dry ice bath. To this solution was added sodium nitrite (5.6g, 82.44mmol), the reaction temperature was maintained at 0°C during this addition. After addition was complete, the dry ice bath was removed and the reaction allowed to warm and stirred at room temperature for 30min. The reaction mixture was
- 10 basified with aqueous NaOH 35%. The resulting precipitate was filtered, washed with water and dried to give the title compound (mixture of two isomers) as a pink solid (20.53g, 93%). This compound was used in the next step without purification; [APCI MS] m/z 321 (MH+).


- 15 Intermediate 119: 2-Hydroximino-2-[2-Bromo-pyridin-4-yl]-1-(pyridin-2-yl)-ethan-1-one



The title compound was obtained from intermediate 39, as described for intermediate 118, as a solid (36g, 98%); m.p. 200°C; [APCI MS] m/z 307 (MH+).

20

Intermediate 120 : 2-tert-butyl-4-(6-methyl-pyridin-2-yl)-5-(2-bromo-pyridin-4-yl)-imidazole



Intermediate 118 (6g, 18.7mmol) was dissolved in acetic acid (50mL) and treated with ammonium acetate (4.33g, 56.1mmol) and pivalaldehyde (2.7g, 37.4mmol). The resulting mixture was heated at reflux for 1 hour, then allowed to cool at room temperature and was concentrated. The residue was dissolved into water and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄ and evaporated to dryness under reduced pressure to give 2-tert-butyl-4-(6-methyl-pyridin-2-yl)-N-1-hydroxy-5-(2-bromo-pyridin-4-yl)-imidazole; (6.31g, 87%). 2-tert-Butyl-4-(6-methyl-pyridin-2-yl)-N-1-hydroxy-5-(2-bromo-pyridin-4-yl)-imidazole (6.31g, 16.21mmol) was dissolved in DMF (60mL), treated with triethyl phosphite (2.78mL, 16.21mmol) and the resulting mixture was heated at 130°C for 5 h. To complete the reaction triethyl phosphite (0.2eq) was added and the mixture was stirred at 130°C for 18h. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with water, dried over Na₂SO₄ and concentrated under reduced pressure. The crude oil was precipitated with diisopropyl ether to afford the title compound as a brown solid (3.88g, 65%); m.p. 200°C; [APCI MS] m/z. 372 (MH+).

The following compounds of formula (IVDa) were prepared by methods analogous to that described for intermediate 120 using the starting materials indicated (see Table 7).





Table 7

Int.	R ²	R ⁴	From Int.	Physical data
121	H	t-butyl	119	[APCI MS] m/z 358 (MH+)

Int.	R ²	R ⁴	From Int.	Physical data
122	methyl	i-propyl	118	[APCI MS] m/z 358 (MH ⁺)
123	H	i-propyl	119	[APCI MS] m/z 343/345 (MH ⁺)
124	methyl	methyl	118	[APCI MS] m/z 330 (MH ⁺)


Intermediate 125: 4-{4-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-pyridin-2-yl}-benzaldehyde



- 5 Intermediate 120 (2g, 5.4mmol) and 4-formylphenyl boronic acid (1.13g, 7.56mmol) were reacted as described for intermediate 99 to afford the title compound as a yellow solid (2.37g, quantitative); [APCI MS] m/z 397 (MH⁺).

Intermediate 126: 4-{4-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-pyridin-2-yl}-phenol

10




- Intermediate 120 (2.5g, 6.7mmol) and 4-hydroxyphenyl boronic acid (1.3g, 9.38mmol) were reacted as described for intermediate 99, to afford the title compound as a brown solid (1.57g, 61%); ¹H NMR (350 MHz; CDCl₃, ppm) δ: 8.37 (1H, d), 7.70 (1H, s), 7.46 (2H, d), 7.30 (1H, t), 7.20-7.10 (2H, m), 6.83 (1H, d), 6.60 (1H, d), 3.85-3.23 (4H, brd), 2.27 (3H, s), 1.27 (9H, s); [APCI MS] m/z 385 (MH⁺).

15

20


Intermediate 127: 4-{4-[2-isopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-pyridin-2-yl}-benzaldehyde



Intermediate 122 (2.05g, 5.74mmol) and 4-formylphenyl boronic acid (1.2g, 8.04mmol) were reacted as described for intermediate 99 to afford the title compound as a pale yellow solid (1.22g, 56%); ¹H NMR (300 MHz; CDCl₃, ppm) δ:

9.90 (1H, s), 8.54 (1H, d), 8.02 (2H, d), 7.79 (2H, d), 7.47-7.16 (3H, m), 6.87 (1H, d),
 3.12-2.95 (1H, m), 2.39(3H, s), 1.25 (6H, d); [APCI MS] m/z 383 (MH⁺).

Intermediate 128: Polymer supported 5-(2-bromo-4-pyridinyl)-4-(2-pyridinyl)-1,3-thiazol-2-amine




Step 1: Rink Argopore resin (12g, 0.58 mmol/g substitution) was placed into a peptide vessel and washed with CH₂Cl₂ (3x100mL). The resin was then treated for 10min with a solution of piperidine 20% in DMF (3x40mL). After washing with DMF (3x100mL) and CH₂Cl₂ (3x100mL), the resin was treated with a solution of Fmoc-NCS (0.2M) in CH₂Cl₂ (170mL) under argon at room temperature for 1h. The resin was washed with DMF (3x100mL), EtOH (3x100mL) and CH₂Cl₂ (3x100mL) and subsequently stirred for 10min with a solution of piperidine 20% in DMF (3x40mL) to give after washing with DMF (3x100mL) and CH₂Cl₂ (3x100mL) the resin bound thiourea.

Step 2 : To a solution of intermediate 39 (8.5g, 29mmol) in dioxane (145mL) was added under argon polymer-supported pyridinium perbromide (1.8mmol/g, 16g). The suspension was shaken under argon at room temperature overnight. The resin was removed by filtration and washed with dioxane (25mL) to give 2-bromo-2-(2-bromo-4-pyridinyl)-1-(2-pyridinyl)ethanone which was used in solution in dioxane without purification in the next step.

Step 3: The product from step 1 was stirred with the product from step 2 (0.18M) in dioxane (175mL) for 4h at room temperature under argon. The resin was washed

with dioxane (3x100mL). A second exposure with the product from step 2 (0.18M in dioxane, 175mL) was performed. The resin was washed with DMF (3x100mL), EtOH (3x100mL), CH₂Cl₂ (3x100mL) and dried under a stream of nitrogen overnight. 2 mg of the obtained resin were cleaved with a solution of TFA 20% in CH₂Cl₂ to give the
 5 title compound which was characterised by LC-MS (purity>96%); [APCI MS] m/z 333, 335, 336 (MH⁺).


Intermediate 129: Polymer supported 5-(2-bromo-4-pyridinyl)-4-(6-methyl-2-pyridinyl)-1,3-thiazol-2-amine



Intermediate 129 was prepared in analogous fashion to intermediate 128 starting from intermediate 40. After step 3, 2 mg of the obtained resin were cleaved with a solution of TFA 20% in CH₂Cl₂ to give the title compound which was characterised by
 15 LC-MS (purity>96%); [APCI MS] m/z 347/ 349/ 350 (MH⁺).

Pyrazole Examples

Example 1: 2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridine




20 To an ice-cooled solution of intermediate 93 (4 g, 7 mmol) in DMF (80 ml) was added portionwise sodium hydride (0.6g, 3 eq, 21 mmol) and the mixture then stirred at room temperature for 30 mins. Intermediate 22 (1.6 g, 10 mmol) was added and the mixture stirred at room temperature overnight and then poured into water and extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄ and filtered.
 25 Evaporation of the solvent in vacuo gave a crude oil which was purified by chromatography on silica gel (CH₂Cl₂/MeOH 97:3) to give the trityl compound as an oil (3 g). This compound was dissolved in methanol (60 ml) and HCl (1N, 40 ml) and the solution was heated under reflux for 2 hours and then concentrated in vacuo. The residue was dissolved in water and washed with CH₂Cl₂. The aqueous layer was

basified with NaOH (1N) and extracted with CH₂Cl₂. The organic extract was washed with water and dried over Na₂SO₄, filtered and evaporated to give a solid which was crystallised from EtOH to give the title compound as white crystals (1.1 g, 37%); m.p. 191°C; TOF MS ES⁺ exact mass calculated for C₂₅H₂₂N₆O : 423.1933


5 (MH⁺). Found : 423.1928 (MH⁺).

Example 2: 2-[4-(Ethylsulfonyl)phenyl]-4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridine



- 10 To a solution of intermediate 82 (0.5 g, 0.9 mmol) in a mixture of DME (18 ml) and water (9 ml) was added 4-(ethylsulfonyl)phenyl boronic acid (1.3 eq, 0.25 g, 1.17 mmol), tetrakis (triphenylphosphine)palladium(0) (0.05 g) and Na₂CO₃ (3 eq, 0.28g, 2.69 mmol) and the reaction mixture was heated under reflux overnight. The cooled mixture was poured into ice and extracted with CH₂Cl₂. The organic layer was
- 15 washed with water, dried over Na₂SO₄ and filtered. Evaporation of the solvent in vacuo gave an oil which was dissolved in MeOH (30 ml) and HCl (1N, 20 ml). The solution was heated under reflux for 3 hours and then concentrated under reduced pressure. The residue was dissolved in water and washed with CH₂Cl₂. The
- 20 aqueous layer was basified with NaOH (1N) and extracted with CH₂Cl₂. The organic extract was washed with water, dried over Na₂SO₄, filtered and evaporated under reduced pressure. After chromatography on silica gel (CH₂Cl₂/MeOH, 95:5) and crystallisation from DMF, the title compound was obtained as white crystals (166 mg, 45.7%); m.p. 244°C; [APCI MS] m/z 405 (MH⁺).

- 25 The following compounds of formula (IAb) were prepared by methods analogous to that described for Example 2 using the starting materials indicated (see Table 9).




(IAb)

Table 9

Ex	R ¹	From Int.	Physical data
3	cyano	82	TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₅ N ₅ (MH ⁺) : 338.1406, found : 338.1408; m.p. 198°C
4	trifluoromethoxy	82	TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₅ F ₃ N ₄ O(MH ⁺) : 397.1276, found : 397.1269; m.p. 131°C
5	chloro	82	TOF MS ES ⁺ exact mass calculated for C ₂₀ H ₁₅ ClN ₄ (MH ⁺) : 347.1063, found : 347.1057; m.p. 190°C
6	methoxy	82	TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₈ N ₄ O(MH ⁺) : 343.1600, found : 343.1600
7	methanesulfonyl	82	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.84 (d, 1H), 8.52 (d, 2H), 8.44 (s, 1H), 8.26 (d, 2H), 8.01 (t, 1H), 7.89-7.68 (m, 2H), 7.50 (d, 1H), 3.51 (s, 3H), 2.64 (s, 3H); m.p. 232-234°C

Example 8: 4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-2-[4-(pyrrolidin-1-ylmethyl)phenyl]pyridine




5

To a solution of intermediate 95 (0.29g, 0.5mmol) and pyrrolidine (4 eq, 0.142g) in dry dichloroethane (20mL) was added acetic acid (1.5eq, 0.05g) followed by sodium triacetoxyborohydride (2eq, 0.224g). The mixture was stirred at room temperature overnight, diluted with water, extracted with CH₂Cl₂ and dried over Na₂SO₄. The solvent was removed under reduced pressure and the resulting product was treated with a mixture of MeOH/ HCl 1N (3:2, 50ml) at reflux for 3h. The reaction mixture was concentrated to dryness to give a residue which was dissolved in water and washed with CH₂Cl₂. The aqueous phase was basified with NaOH (1N), extracted with CH₂Cl₂ and dried over Na₂SO₄. Concentration to dryness gave a solid which was precipitated from a mixture CH₂Cl₂/hexane to give the title compound as (0.095g, 48%) ; ¹H NMR (CDCl₃) δ 8.62 (d, 1H); 7.88 (d, 2H); 7.71 (d, 2H); 7.50-7.39 (m, 3H); 7.26-7.20 (m, 2H); 7.05 (d, 1H); 3.76 (brs, 2H); 2.79-2.56 (m, 4H); 2.53 (s, 3H); 1.91-1.75 (m, 4H); TOF MS ES⁺ exact mass calculated for C₂₅H₂₅N₅ : 396.2188(MH⁺); Found : 396.2174(MH⁺).

20

The following compounds of formula (IAa) were prepared by methods analogous to that described for Example 8 using the starting materials indicated (see Table 10).




(IAa)

Table 10

5


Ex	R ¹	R ⁴	From Int.	Physical data
9	(morpholin-4-yl)methyl	H	95	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ O(MH ⁺): 412.2137, found : 412.2150; ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.7 (d, 1H), 7.98 (d, 2H), 7.81 (d, 2H), 7.58-7.41 (m, 3H), 7.37-7.3 (m, 2H), 7.14 (d, 1H), 3.89-3.7 (m, 4H), 3.62 (brs, 2H), 2.62 (s, 3H), 2.6-2.47 (m, 4H)
10	(N-methyl-2-methoxyethylamino)methyl	H	95	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.59 (d, 1H), 7.83 (d, 2H), 7.71 (s, 1H), 7.66 (s, 1H), 7.47-7.29 (m, 3H), 7.24-7.18 (m, 2H), 7.03 (d, 1H), 3.59-3.5 (m, 2H), 3.45 (brt, 2H), 3.25 (s, 3H), 2.56 (brt, 3H), 2.60-2.47 (m, 4H), 2.5 (s, 3H)
11	(4-methoxy-piperidin-1-yl)methyl	H	95	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₉ N ₅ O: 440.2450(MH ⁺), found : 440.2438(MH ⁺); ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.64 (d, 1H), 7.88 (d, 2H), 7.76 (s, 1H), 7.72 (s, 1H), 7.47, (t, 1H), 7.44-7.35 (m, 2H), 7.29-7.23 (m, 2H), 7.09 (d, 1H), 3.61-3.50 (m, 2H), 3.29 (s, 3H), 3.26-3.14 (m, 1H), 2.81-2.66 (m, 2H), 2.56 (s, 3H), 2.30-2.08 (m, 2H), 2.01-1.82 (m, 2H), 1.69-1.52 (m, 2H)
12	(morpholin-4-yl)methyl	methyl	98	[APCI MS] m/z 426 (MH ⁺) ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.66 (d, 1H), 7.86 (d, 2H), 7.64 (s, 1H), 7.44-7.30 (m, 3H), 7.15-7.11 (m, 1H), 7.03-6.89 (m, 2H), 3.74-3.60 (m, 4H), 3.51 (brs, 2H), 2.50 (s, 3H), 2.40-2.34 (m, 4H), 2.25 (s, 3H)

Example 13: 4-(4-{4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzoyl)morpholine




To a solution of intermediate 94 (0.2g, 0.34mmol, 1eq.) in CH₂Cl₂ (50mL) were added morpholine (0.035g, 0.4mmol), HOBT (0.59g, 1.3eq.), EDCI (0.83g, 1.3eq.) and Et₃N (0.04g, 2.3eq.) and the reaction mixture was stirred at room temperature overnight. The reaction was hydrolysed and extracted with CH₂Cl₂. The solvent was removed under reduced pressure. The residue was treated with MeOH/ HCl 1N (3/2, 30ml) at reflux for 1h. After removal of the solvent under reduced pressure, the residue was dissolved in water and washed with CH₂Cl₂. The aqueous phase was basified with NaOH 1N and extracted with CH₂Cl₂. The organic phase was dried, filtered, and evaporated to dryness to give a crude solid which was precipitated with a mixture CH₂Cl₂/hexane to give the title compound (0.075g; 52%); ¹H NMR (300MHz, CDCl₃) δ 8.63 (1H, d); 7.95 (2H, d); 7.76 (2H, s); 7.52-7.42 (3H, m); 7.27 (2H, d); 7.12-7.01 (1H, m); 3.50-3.32 (8H, m); 2.51 (3H, brs); TOF MS ES⁺ exact mass calculated for C₂₅H₂₃N₅O₂: 426.1930(MH⁺). Found : 426.1931(MH⁺).

Example 14: 4-{4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide



Intermediate 94 (0.4g, 0.67mmol) and 4-aminotetrahydropyran (0.081g, 0.8mmol) were reacted as was described for example 13 to give the title compound (0.2g, 68%); m.p. 148°C; TOF MS ES⁺ exact mass calculated for C₂₆H₂₅N₅O₂: 440.2086(MH⁺). Found : 440.2060(MH⁺).


Example 15: N-(4-{4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}phenyl)-2-morpholin-4-ylacetamide



Intermediate 97 (0.38g, 0.67mmol) and 4-morpholinylacetic acid hydrochloride (0.156g, 0.86mmol) were reacted as was described for example 13 to give the title compound as an off-white solid (0.115g, 38%); ¹H NMR (300MHz, CDCl₃) δ 9.10 (1H, s); 8.58(1H, d); 7.87 (2H, d); 7.70 (2H, s); 7.59 (2H, d); 7.28-7.18 (2H, m); 7.10-

6.97 (1H, m); 3.71 (4H, t); 3.08 (3H, s); 2.56 (4H, t); 2.50 (3H, s); TOF MS ES⁺ exact mass calculated for C₂₆H₂₆N₆O₂: 455.2195 (MH⁺). Found : 455.2195 (MH⁺).


Example 16: 4-(4-{4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}phenyl)morpholine



Step 1: To a solution of intermediate 96 (0.633g, 1mmol) in toluene (10ml) were added morpholine (0.348g, 4mmol, 4eq), Pd₂(dba)₃ (0.045g, 0.049mmol, 0.05eq), binap (0.062g, 0.1mmol, 0.1eq) and t-BuOK (0.134g, 1.4mmol, 1.4eq) and the reaction mixture was refluxed for 5 hours. The mixture was then poured into ice and extracted with EtOAc. The organic phase was washed with water and dried over Na₂SO₄. Concentration to dryness gave a crude product that was purified by chromatography on silica gel (CH₂Cl₂/CH₃OH 98:2) to afford 4-(4-{4-[3-(6-methyl-2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl}phenyl)morpholine.

Step 2: 4-(4-{4-[3-(6-Methyl-2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl}phenyl)morpholine was treated with a mixture of MeOH/HCl 1N (3 :2, 50ml) under reflux for 2 hours. The reaction mixture was poured into water and extracted with CH₂Cl₂. The aqueous phase was basified with NaOH (1N) and extracted with CH₂Cl₂. The organic phase was washed with water, dried and evaporated to dryness to give a crude product which was precipitated with a mixture of CH₂Cl₂/ hexane to afford the title compound as a yellow solid (0.31g, 78%); TOF MS ES⁺ exact mass calculated for C₂₄H₂₃N₅O: 398.1981 (MH⁺). Found 398.1961(MH⁺).


Example 17: 2-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-4-[3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]pyridine



Intermediate 96 (0.308g, 0.5mmol) and 2-methyl-1H-imidazole (0.82g, 1mmol) were reacted as described for example 16 to give the title compound as a white solid


(0.013g, 6%); m.p. 128°C; ¹H NMR (300 MHz; CDCl₃) δ: 8.64 (1H, d), 8.02 (2H, d), 7.75 (2H, d), 7.48 (1H, t), 7.37-7.20 (4H, m), 7.19 (1H, s), 7.08 (1H, d), 6.99 (2H, d), 2.52 (3H, s), 2.35 (3H, s).

5 Example 18: 3-[2-(4-((tetrahydropyran-4-yl)aminocarbonyl)phenyl)pyridin-4-yl]-4-[6-methylpyridin-2-yl]-1H-pyrazole



To a solution of intermediate 71 (0.6g, 1.44 mmol) in DMF (10ml) and acetic acid (0.2ml, 3.47 mmol) was added DMF.DMA (0.258g, 2.16 mmol) and the mixture was
 10 stirred at room temperature for 2 h. Hydrazine hydrate (3ml) was added and the mixture was stirred at room temperature overnight, then was heated at 40°C for 2 h and then poured into water. The aqueous phase was extracted with CH₂Cl₂, the organic phase dried over Na₂SO₄ and concentrated under reduced pressure. The
 residue was purified by chromatography on silica gel, eluting with CH₂Cl₂/MeOH
 15 (95/5). After crystallisation from EtOAc, the title compound was obtained as white crystals (0.2g, 31.51%); m.p. 170°C; TOF MS ES⁺ exact mass calculated for C₂₆H₂₅N₅O₂: 440.2086 (MH⁺). Found 440.2065 (MH⁺).

The following compounds of formula (IAb) were prepared by methods analogous to
 20 that described for Example 18 using the starting materials indicated (see Table 11).



(IAb)


Table 11

Ex	R ¹	From Int.	Physical data
19	(4-ethylpiperazin-1-yl)carbonyl	70	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₈ N ₆ O(MH ⁺): 453.2403, found: 453.2394 m.p. 126°C
20	morpholin-4-yl	72	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ O(MH ⁺): 398.1981, found: 398.1955 m.p. 210°C
21	(morpholin-4-yl)methyl	77	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ O(MH ⁺): 412.2137, found: 412.2120

Ex	R ¹	From Int.	Physical data
			m.p. 128°C
22	2-(pyrrolidin-1-yl)ethoxy	73	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₇ N ₅ O(MH ⁺) : 426.2294, found : 426.2254 m.p. 96°C
23	(morpholin-4-yl)carbonylmethoxy	75	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₃ (MH ⁺) : 456.2036, found : 456.2012 m.p. 170°C

Triazole Examples

Example 24 : 2-(4-Methanesulfonylphenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine



5


To a solution of intermediate 5 (700mg, 2 mmol) in dry DMF (13 ml) was added azidotrimethylsilane (8 mmol, 930mg) and the reaction mixture was stirred at 100°C overnight. The reaction mixture was hydrolysed with water and extracted with CH₂Cl₂. The organic phase was washed with water, dried over Na₂SO₄ and filtered.

10

Evaporation of the solvent in vacuo gave a crude product which was purified by chromatography on silica gel (toluene / isopropylamine 95:5). The crude oil was precipitated in a mixture CH₂Cl₂/hexane to give the title compound as a yellow powder (260mg, 33.2%), gummy at 150°C; ¹H NMR (300 MHz, CDCl₃) δ: 8.70 (1H, d), 8.28 (1H, s), 8.15 (2H, d), 7.95 (2H, d), 7.70-7.57 (2H, m), 7.50 (1H, d), 7.15 (1H, d), 3.00 (3H, s), 2.50 (3H, s), NH triazole not observed ; TOF MS ES⁺ exact mass calculated for C₂₀H₁₇N₅O₂S: 392.1181(MH⁺). Found : 392.1218(MH⁺) .

15

The following compounds of formula (IBa) were prepared by methods analogous to that described for Example 24 using the starting materials indicated (see Table 11).



(IBa)


Table 11

20

Ex	R ¹	From Int.	Physical data
25	methoxy	6	TOF MS ES ⁺ exact mass calculated for C ₂₀ H ₁₇ N ₅ O(MH ⁺)/ 344.1511. Found: 344.1506.
26	2-(N,N-dimethylamino)-ethoxy	16	TOF MS ES ⁺ exact mass calculated for C ₂₃ H ₂₄ N ₆ O(MH ⁺): 401.2090. Found: 401.2063. m.p. 143°C
27	morpholinomethyl	15	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₄ N ₆ O (MH ⁺): 413.2090 . Found: 413.2110. m.p. 110°C
28	ethyl	9	[APCI MS] m/z 342 (MH ⁺) TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₉ N ₅ (MH ⁺): 342.1718. Found : 342.1716.
29	tetrahydropyran-4-ylaminocarbonyl	7	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₄ N ₆ O (MH ⁺): 441.2039. Found: 441.2032.
30	chloro	10	TOF MS ES ⁺ exact mass calculated for C ₁₉ H ₁₄ ClN ₅ (MH ⁺): 348.1016 Found:348.1000; m.p. 144°C
31	trifluoromethoxy	11	TOF MS ES ⁺ exact mass calculated for C ₂₀ H ₁₄ F ₃ N ₅ O(MH ⁺): 398.1229. Found: 398.1194; m.p. 128°C
32	2-(pyrrolidin-1-yl)ethoxy	12	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₆ N ₆ O (MH ⁺): 427.2246. Found: 427.2277.
33	fluoro	13	TOF MS ES ⁺ exact mass calculated for C ₁₉ H ₁₄ FN ₅ (MH ⁺): 332.1311. Found: 332.1345.

Imidazopyridine Examples

Example 34: 3-[2-(4-methoxyphenyl)-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-a]pyridine




5

A solution of intermediate 84 (500mg, 1.42 mmol) in toluene (10 ml) was treated with tetrakis(triphenylphosphine)palladium(0) (165mg, 10%mol) and stirred at room temperature for 30 min. Na₂CO₃ (2M) (0.6 ml) was added to the reaction mixture, followed by 4-methoxyphenyl boronic acid (282mg, 1.3eq, 1.85 mmol). The resulting mixture was heated under reflux overnight. The cooled mixture was poured into ice and extracted with toluene. The organic layer was washed with water, dried over Na₂SO₄ and filtered. Evaporation of the solvent in vacuo gave a crude oil which was purified by chromatography on silica gel (CH₂Cl₂/MeOH, 90/10) and triturated in CH₂Cl₂/pentane to give the title compound as a cream powder (68mg, 13%); m.p. 222°C; TOF MS ES⁺ exact mass calculated for C₂₄H₁₈N₄O : 379.1559(MH⁺). Found: 379.1540 (MH⁺).

15

The following compounds of formula (ICj) were prepared by methods analogous to that described for Example 34 using the starting materials indicated (see Table 12).




(ICj)

Table 12

Ex	R ¹	R ⁴	R ²	From Int.	Physical data
35	methoxy	H	methyl	85	[APCI MS] m/z : 393 (MH ⁺) m.p. 174°C
36	trifluoromethoxy	H	methyl	85	[APCI MS] m/z : 447 (MH ⁺) m.p. 120°C
37	cyano	H	methyl	85	[APCI MS] m/z : 388 (MH ⁺) m.p. 214°C
38	methanesulfonyl	H	H	84	[APCI MS] m/z : 427 (MH ⁺) m.p. 242-244°C
39	methanesulfonyl	H	methyl	85	[APCI MS] m/z : 441 (MH ⁺) ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.85 (d, 1H), 8.2 (d, 1H), 8.14 (d, 1H), 8.09 (m, 2H), 7.82 (d, 1H), 7.74 (d, 1H), 7.58 (m, 2H), 7.53 (m, 1H), 7.44 (dd, 1H), 7.3 (t, 1H), 7.05 (d, 1H), 6.85 (t, 1H), 3.09 (s, 3H), 2.31 (s, 3H)
40	methanesulfonyl	8-methyl	methyl	90	[APCI MS] m/z : 455 (MH ⁺) ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.85 (d, 1H), 8.2 (d, 2H), 8.05 (m, 3H), 7.85 (d, 1H), 7.5 (m, 3H), 7.1 (m, 2H), 6.8 (t, 1H), 3.1 (s, 3H), 2.75 (s, 3H), 2.35 (s, 3H)
41	acetyl	H	H	84	[APCI MS] m/z : 391 (MH ⁺) m.p. 214°C
42	methylcarbonyl amino	H	H	84	[APCI MS] m/z : 406 (MH ⁺) m.p. 133°C
43	methylcarbonyl amino	H	methyl	85	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₁ N ₅ O (MH ⁺): 420.1824. Found: 420.1808. m.p. 257°C
44	(tetrahydropyran-4-yl)amino carbonyl	H	H	84+33	[APCI MS] m/z : 476 (MH ⁺) m.p. 179°C

Ex	R ¹	R ⁴	R ²	From Int.	Physical data
45	(tetrahydropyran-4-yl)amino carbonyl	H	methyl	85+33	[APCI MS] m/z : 490 (MH+) m.p. 128°C
47	(morpholin-4-yl)carbonyl	8-methyl	methyl	90+35	[APCI MS] m/z : 490 (MH+)
48	(4-ethylpiperazin-1-yl)carbonyl	8-methyl	methyl	90+36	TOF MS ES ⁺ exact mass calculated for C ₃₂ H ₃₂ N ₆ O(MH ⁺) : 517.2715, found : 517.2751 m.p. 212°C
49	(morpholin-4-yl)carbonyl	H	fluoro	92+35	TOF MS ES ⁺ exact mass calculated for C ₂₈ H ₂₂ FN ₅ O ₂ (MH ⁺) : 480.1836, found : 480.1756 m.p. 191°C

The following compounds of formula (ICK) were prepared by methods analogous to that described for Example 34 using the starting materials indicated (see Table 13).




(ICK

5

Table 13


Ex.	R ¹	From Int.	Physical data
50	methanesulfonyl amino	91+34	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₁₉ ClN ₄ O ₂ S(MH ⁺) : 475.0995, found : 475.0975; m.p. 60°C (becomes gummy)
51	(tetrahydropyran-4-yl)amino carbonyl	91+33	¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 7.85 (d, 2H), 7.75 (d, 2H), 7.65-7.55 (m, 4H), 7.45-7.35 (m, 6H), 7.2 (m, 1H), 6 (d, 1H), 4.2 (m, 1H), 4 (m, 2H), 3.5 (m, 2H), 2, (m, 2H), 1.6 (m, 2H); m.p. 234°C.

Example 52: 2-(6-methyl-pyridin-2-yl)-3-{2-[4-amino-phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine




A solution of example 43 (2.3g, 5.48 mmol) in MeOH (50 ml) and HCl 1N (50 ml) was stirred at room temperature for 18 hours and then basified with a solution of NaOH 1N. After extraction with CH₂Cl₂, the organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The title compound was obtained as a yellow solid (0.79g, 38%); [APCI MS] m/z: 378 (MH⁺); ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.7 (d, 1H), 8.1 (d, 1H), 7.85 (m, 3H), 7.7 (d, 1H), 7.6 (d, 1H), 7.45 (t, 1H), 7.25 (m, 2H), 7 (d, 1H), 6.8 (t, 1H), 6.7 (d, 2H), 3.85 (m, 2H), 2.4 (s, 3H).

Example 53 : 2-(6-methyl-pyridin-2-yl)-3-{2-[4-(trifluoromethylsulfonylamino)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



To a solution of example 52 (390mg, 1.03mmol) in CH₂Cl₂ (10ml) were added trifluoromethanesulfonic anhydride (0.2ml, 8.55mmol) and triethylamine (0.17 ml, 1.24 mmol) and the mixture was stirred at room temperature for 3 days and then poured into water. After extraction with CH₂Cl₂, the organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with CH₂Cl₂/MeOH (9/1). The title compound was obtained as a yellow foam (178mg, 33.8%); m.p. 135°C; TOF MS ES⁺ exact mass calculated for C₂₅H₁₈F₃N₅O₂S: 510.1212(MH⁺). Found: 510.1229(MH⁺).


Example 54 : 3-[2-(4-(morpholin-4-yl)-phenyl)-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-a]pyridine



A mixture of intermediate 112 (400 mg, 0.93 mmol), morpholine (1.2 eq, 0.1 ml, 1.1 mmol); Pd₂(dba)₃ (0.05 eq, 43 mg, 0.05 mmol), BINAP (0.15 eq, 88 mg, 0.14 mmol) and potassium tert-butoxide (1.4 eq, 126 mg, 1.31 mmol) in toluene (50 ml) was heated under reflux for 2 hours. After dilution with CH₂Cl₂, the organic phase was

washed with water and dried (Na_2SO_4). The solvent was removed under reduced pressure and the resulting residue purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (98 :2, 95 :5 and then 93:7). The resulting oil was crystallised from CH_2Cl_2 /pentane to give the title compound as a yellow solid (140 mg, 35%);
 5 m.p. 145°C (becomes gummy); TOF MS ES^+ exact mass calculated for $\text{C}_{27}\text{H}_{23}\text{N}_5\text{O}$: 434.1981(MH⁺). Found: 434.1993(MH⁺).


Example 55 : 3-[2-[4-(4-methylpiperazin-1-yl)-phenyl]-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-a]pyridine



10


Intermediate 112 (400mg, 0.94mmol) and N-methyl-piperazine (0.125 ml, 1.2eq, 1.13 mmol) were coupled and treated as described for example 54 to afford, after crystallisation in CH_2Cl_2 /diisopropyl ether, the title compound as cream crystals
 15 (70mg, 17%); m.p. 150°C (become gummy); [APCI MS] m/z 447 (MH⁺).

Example 56 : 2-(6-methyl-pyridin-2-yl)-3-[2-(4-(morpholin-4-ylmethyl)phenyl)-pyridin-4-yl]-imidazo[1,2-a]pyridine



20 To a solution of intermediate 99 (310mg, 0.79mmol) and morpholine (1.5 eq, 0.1ml, 1.2mmol) in dry dichloroethane (30ml) was added sodium triacetoxyborohydride (1.5eq, 253mg, 1.2 mmol) and the mixture was stirred for 3 hours at room temperature. The mixture was basified with NaOH 1N, the aqueous layer was extracted with CH_2Cl_2 and dried over Na_2SO_4 . The resulting product was
 25 recrystallised from ethyl acetate to give the title compound as a white powder (194mg, 53%); m.p. 156°C ; [APCI MS] m/z 462 (MH⁺).

The following compounds of formula (ICj) were prepared by methods analogous to that described for Example 56 using the starting materials indicated (see Table 14).



5

Table 14

Ex.	R ¹	R ⁴	R ²	From Int.	Physical data
57	(morpholin-4-yl)-methyl	H	H	100	[APCI MS] m/z 448 (MH ⁺) m.p. 80°C (degradation)
58	(morpholin-4-yl)-methyl	6-chloro	methyl	103	[APCI MS] m/z 496 (MH ⁺) m.p. 157°C
59	(morpholin-4-yl)-methyl	7-methyl	methyl	104	TOF MS ES ⁺ exact mass calculated for C ₃₀ H ₂₉ N ₅ O (MH ⁺): 476.2450. Found: 476.2445; m.p. 188°C
60	(pyrrolidin-1-yl)-methyl	6-chloro	methyl	103	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₂₆ ClN ₅ (MH ⁺): 480.1955. Found: 480.1900; m.p. 134°C
61	(morpholin-4-yl)-methyl	8-methyl	methyl	105	[APCI MS] m/z 476 (MH ⁺) m.p. 122°C
62	(pyrrolidin-1-yl)-methyl	8-methyl	methyl	105	¹ H NMR (300MHz, DMSO d ₆ , ppm) δ : 8.95 (d, 1H), 8.45 (m, 2H), 8.2 (d, 2H), 7.95 (t, 1H), 7.8 (d, 2H), 7.75 (m, 3H), 7.5 (d, 1H), 7.25 (t, 1H), 4.4 (m, 2H), 3.3 (m, 2H), 3.05 (m, 2H), 2.95 (s, 3H), 2.5 (s, 3H), 2.05 (m, 2H), 1.9 (m, 2H); m.p : 197°C

The following compounds of formula (ICm) were prepared by methods analogous to that described for Example 56 using the starting materials indicated (see Table 15).

10





Table 15

Ex.	R ¹	R ²	R ³	From Int.	Physical data
63	(morpholin-4-yl)-methyl	chloro	fluoro	101	[APCI MS] m/z 499 (MH ⁺) m.p. 189°C
64	(pyrrolidin-1-yl)-methyl	fluoro	fluoro	102	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₂₄ F ₂ N ₄ (MH ⁺): 467.2047. Found: 467.2063 m.p. 155°C
65	(morpholin-4-yl)-methyl	fluoro	fluoro	102	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₂₄ F ₂ N ₄ O (MH ⁺): 483.1996. Found: 483.2030 m.p. 205°C

Example 66 : 2-(6-methyl-pyridin-2-yl)-3-{2-[4-((morpholin-4-yl)carbonyl)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine




5

To a solution of intermediate 106 (500mg, 1.23mmol) in DMF (30ml) were added morpholine (0.13ml, 1.48mmol), HOBT (200mg, 1.48mmol), EDCI (283mg, 1.48mmol) and triethylamine (0.2ml; 1.48mmol) and the mixture was stirred at room temperature overnight and then diluted with CH₂Cl₂. The organic phase was washed with sodium hydroxide solution 1N, then water, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with CH₂Cl₂/MeOH (95 :5). After trituration with diisopropyl ether, the title compound was obtained as a pale yellow solid (147mg, 25.13%); m.p. 110°C; [APCI MS] m/z 476 (MH⁺).

10
15


Example 67 : 2-(6-methyl-pyridin-2-yl)-3-{2-[4-((3-methoxypropylamino)carbonyl)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



Intermediate 106 (400mg, 0.98mmol) and 3-methoxypropylamine (0.11ml, 1.18mmol) were coupled and treated as described for example 66 to afford, after trituration with CH₂Cl₂/pentane, the title compound as a pale yellow solid (210mg, 44.69%); m.p. 165°C; [APCI MS] m/z 478 (MH⁺).

5

Example 68: 2-(pyridin-2-yl)-3-{2-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



A solution of intermediate 113 (140 mg, 0.3mmol) and pyrrolidine (0.75ml, 9 mmol) in EtOH (5 ml) was heated under reflux for 6 days. After cooling, water was added and the product was extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The resulting residue was purified by chromatography on silica gel eluting with CH₂Cl₂/MeOH/TEA (80/20/1%). The title compound was obtained as a brown gum (13 mg, 10%); [APCI MS] m/z 462 (MH⁺); ¹H NMR (300 MHz, CDCl₃) δppm: 8.75 (d, 1H), 8.5 (d, 1H), 8.15 (d, 1H), 7.9 (m, 3H), 7.85 (s, 1H), 7.7 (m, 2H), 7.3 (m, 2H), 7.2 (m, 1H), 7 (d, 2H), 6.85 (t, 1H), 4.2 (t, 2H), 3 (t, 2H), 2.75 (m, 4H), 1.85 (m, 4H).

The following compounds of formula (ICp) were prepared by methods analogous to that described for Example 68 using the starting materials indicated (see Table 16).





Table 16

Ex.	R ⁵ R ⁶ N	R ⁴	From Int.	Physical data
-----	---------------------------------	----------------	-----------	---------------

Ex.	R ⁵ R ⁶ N	R ⁴	From Int.	Physical data
69	dimethyl amino	H	114	[APCI MS] m/z : 450 (MH+); ¹ H NMR (300MHz, CDCl ₃ , ppm) δ : 8.8 (d, 1H), 8.2 (d, 1H), 7.95 (m, 3H), 7.75 (m, 2H), 7.6 (t, 1H), 7.4 (d, 1H), 7.3 (m, 1H), 7.05 (m, 3H), 6.9 (t, 1H), 4.25 (t, 2H), 3 (t, 2H), 2.55 (s, 6H), 2.4 (s, 3H)
70	pyrrolidin-1-yl	7-methyl	116	TOF MS ES ⁺ exact mass calculated for C ₃₁ H ₃₁ N ₅ O (MH+): 490.2607. Found: 490.2600; m.p. 163°C
71	morpholin-4-yl	7-methyl	116	TOF MS ES ⁺ exact mass calculated for C ₃₁ H ₃₁ N ₅ O ₂ (MH+): 506.2556. Found: 506.2534; ¹ H NMR (300 MHz, CDCl ₃ , ppm) δ: 8.8 (d, 1H), 8.05 (d, 1H), 7.9 (m, 3H), 7.7 (d, 1H), 7.6 (t, 1H), 7.5 (s, 1H), 7.35 (d, 1H), 7 (m, 3H), 6.7 (d, 1H), 4.2 (t, 2H), 3.8 (m, 4H), 2.85 (t, 2H), 2.6 (m, 4H), 2.45 (s, 3H), 2.4 (s, 3H)
72	pyrrolidin-1-yl	8-methyl	117	[APCI MS] m/z : 490 (MH+); ¹ H NMR (300 MHz, CDCl ₃ , ppm) δ: 8.75 (d, 1H), 8.05 (d, 1H), 7.9 (m, 3H), 7.7 (d, 1H), 7.55 (t, 1H), 7.3 (d, 1H), 7.05 (m, 2H), 6.95 (d, 2H), 6.7 (t, 1H), 4.25 (t, 2H), 3.05 (t, 2H), 2.9 (m, 4H), 2.7 (s, 3H), 2.4 (s, 3H), 1.95 (m, 4H)

The following compounds of formula (ICq) were prepared by methods analogous to that described for Example 68 using the starting materials indicated (see Table 17).




(ICq)

5

Table 17


Ex.	R ⁵ R ⁶ N	From Int.	Physical data
73	dimethylamino	115	TOF MS ES ⁺ exact mass calculated for C ₂₈ H ₂₅ ClN ₄ O (MH+): 469.1795. Found: 469.1723; ¹ H NMR (300 MHz, CDCl ₃ , ppm) δ: 8.8 (d, 1H), 8.1 (d, 1H), 7.9 (d, 2H), 7.8 (s, 1H), 7.7 (m, 2H), 7.45 (d, 1H), 7.25 (m, 3H), 7.2 (m, 1H), 7 (d, 2H), 6.85 (t, 1H), 4.35 (t, 2H), 3.25 (t, 2H), 2.7 (s, 6H)
74	pyrrolidin-1-yl	115	TOF MS ES ⁺ exact mass calculated for C ₃₀ H ₂₇ ClN ₄ O (MH+): 495.1952. Found: 495.1957; m.p. 298°C

Example 75: 7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-((1-methyl-imidazol-4-yl)methoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



To a solution of intermediate 111 (400mg, 1.02mmol) in DMF (20ml) was added
 5 portionwise sodium hydride (60% in mineral oil, 101mg, 2.55mmol) and the mixture
 was stirred at room temperature for 20 minutes. Intermediate 22 (173mg, 1.32mmol)
 was then added and the mixture was heated at 60°C for 3 days and then poured into
 water. After extraction with CH₂Cl₂, the organic phase was dried over Na₂SO₄ and
 concentrated under reduced pressure. The residue was purified by chromatography
 10 on silica gel eluting with CH₂Cl₂/MeOH (90 :10). After trituration with diisopropyl
 oxide, the title compound was obtained as a yellow solid (130mg, 26%); m.p. 217°C;
 TOF MS ES⁺ exact mass calculated for C₃₀H₂₆N₆O: 487.2246(MH⁺). Found:
 487.2247(MH⁺).


15 Example 76: 2-(6-methyl-pyridin-2-yl)-3-{2-[4-((1-methyl-imidazol-4-yl)methoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



Intermediate 108 (400mg, 1.06mmol) and intermediate 22 (212mg, 1.27mmol) were
 coupled and treated as described for example 75 to afford, after trituration with
 20 diisopropyl oxide, the title compound as a white solid (200mg, 40%); m.p. 120°C;
 [APCI MS] m/z 473 (MH⁺).

Example 77: 7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4(aminocarbonylmethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine


93



To a solution of intermediate 111 (500mg, 1.27mmol) in acetone (25ml) were added cesium carbonate (623mg, 1.91mmol) and bromoacetamide (264mg, 1.91mmol) and the mixture was heated under reflux for 48 hours and then poured into water. After
 5 extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (95/5). After trituration with pentane/ethyl acetate, the title compound was obtained as a pale yellow solid (133mg, 23%); m.p. 213°C ; [APCI MS] m/z 450 (MH^+).


10

Example 78 : 8-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-(aminocarbonylmethyloxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine




15 Intermediate 110 (500mg, 1.27mmol) and bromoacetamide (264mg, 1.91mmol) were coupled and treated as described for example 77 to afford, after trituration with diisopropyl oxide, the title compound as a cream solid (80mg, 14%); m.p. 183°C ; [APCI MS] m/z 450 (MH^+).

20 Example 79: 2-(6-methyl-pyridin-2-yl)-3-{2-[4-(morpholin-4-yl)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



To a solution of intermediate 48 (3g, 8.04mmol) in CH_2Cl_2 (80 ml) was added bromine-polymer-supported (5.03g, 8.04 mmol) and the suspension was stirred at room temperature for 3 hours. The resin was removed by filtration, with the filtrate being added directly to 2-amino-pyridine (1.51g, 16.08 mmol) and the resin washed many times with ethanol. The filtrate was heated at reflux for 18 hours, allowed to cool and concentrated. The residue was treated with water and extracted with CH_2Cl_2 . The organic phase was dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 98/2 then 95 :5) to give an oil which crystallised by trituration from diisopropyl oxide. The title compound was obtained as cream crystals (1.2g; 33.38%); m.p. 190 °C; TOF MS ES^+ exact mass calculated for $\text{C}_{28}\text{H}_{25}\text{N}_5\text{O}$ (MH^+): 448.2137. Found: 448.2081


Example 80 : 7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-(morpholin-4-yl)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine



Intermediate 48 (1.27g, 3.4 mmol) was reacted as described for example 79, to afford after trituration with diisopropyl oxide, the title compound as cream crystals (0.6g, 38.22%); m.p. 208°C; TOF MS ES^+ exact mass calculated for $\text{C}_{29}\text{H}_{27}\text{N}_5\text{O}$ (MH^+): 462.2294. Found: 462.2263

Imidazole Examples

Example 81 : N-(tetrahydropyran-4-yl)-4-(4-{2-tert-Butyl-5-[6-methyl-pyridin-2-yl]-1H-imidazol-4-yl}-pyridin-2-yl)-benzamide




25

To a solution of intermediate 120 (0.95g, 2.56mmol) in a mixture of DME (30ml) and water (15ml) were added intermediate 33 (0.93g, 2.81mmol), tetrakis(triphenylphosphine) palladium(0) (0.1g, 0.086mmol) and Na_2CO_3 (solution

2M, 5ml) and the mixture was heated under reflux overnight and then poured into water. After extraction with CH_2Cl_2 , the organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was recrystallised from EtOAc to afford the title compound as yellow crystals (0.77g, 55.36%); m.p. 174°C ; TOF MS ES^+ exact mass calculated for $\text{C}_{30}\text{H}_{33}\text{N}_5\text{O}_2$: 496.2712(MH⁺). Found : 496.2662 (MH⁺).

The following compounds of formula (IDf) were prepared by methods analogous to that described for Example 81 using the starting materials indicated (see Table 18).



(IDf)


Table 18

Ex.	R ¹	R ⁴	R ²	From Int.	Physical data
82	(tetrahydro-pyran-4-yl)-amino-carbonyl	t-butyl	H	121+33	TOF MS ES^+ exact mass calculated for $\text{C}_{29}\text{H}_{31}\text{N}_5\text{O}_2$ (MH ⁺): 482.2556. Found : 482.2577; m.p. 182°C
83	methoxy	t-butyl	H	121	TOF MS ES^+ exact mass calculated for $\text{C}_{24}\text{H}_{24}\text{N}_4\text{O}$ (MH ⁺): 385.2028. Found : 385.2026; m.p. 143°C
84	methane-sulfonyl	t-butyl	methyl	120	TOF MS ES^+ exact mass calculated for $\text{C}_{25}\text{H}_{26}\text{N}_4\text{O}_2\text{S}$ (MH ⁺): 447.1855. Found : 447.1905; m.p. 144°C
85	chloro	t-butyl	methyl	120	TOF MS ES^+ exact mass calculated for $\text{C}_{24}\text{H}_{23}\text{ClN}_4$ (MH ⁺): 403.1689. Found : 403.1637; m.p. 122°C
86	morpholin-4-yl	t-butyl	methyl	120+27	TOF MS ES^+ exact mass calculated for $\text{C}_{28}\text{H}_{31}\text{N}_5\text{O}$ (MH ⁺): 454.2607. Found : 454.2576; m.p. 238°C
87	trifluoro-methoxy	t-butyl	methyl	120	TOF MS ES^+ exact mass calculated for $\text{C}_{25}\text{H}_{23}\text{F}_3\text{N}_4\text{O}$ (MH ⁺): 453.1902. Found : 453.1863; m.p. 179°C
88	(morpholin-4-yl) carbonyl	t-butyl	methyl	120+35	TOF MS ES^+ exact mass calculated for $\text{C}_{29}\text{H}_{31}\text{N}_5\text{O}_2$ (MH ⁺): 482.2556. Found : 482.2517; m.p. 180°C

Ex.	R ¹	R ⁴	R ²	From Int.	Physical data
89	(4-ethyl-piperazin-1-yl)carbonyl	t-butyl	methyl	120+36	TOF MS ES ⁺ exact mass calculated for C ₃₁ H ₃₆ N ₆ O (MH ⁺): 509.3029. Found : 509.3025; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.53 (1H, d), 7.93-7.84 (3H, m), 7.40 (1H, d), 7.37-7.27 (3H, m), 7.18 (1H, d), 6.86 (1H, d), 3.85-3.23 (4H, brd), 2.53-2.21 (9H, m), 1.31 (9H, s), 0.99 (3H, brs).
90	morpholin-4-yl	t-butyl	H	121+27	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₉ N ₅ O (MH ⁺): 440.2450. Found : 440.2401; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 9.92 (1H, brs), 8.47 (1H, d), 8.38 (1H, d), 7.81 (2H, d), 7.77 (1H, s), 7.36 (2H, d), 7.27 (1H, d), 6.95 (1H, dd), 6.80 (2H, d), 3.70 (4H, brt), 3.06 (4H, brt), 1.30 (9H, s).
91	4-ethyl-piperazin-1-yl	t-butyl	H	121+28	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₃₄ N ₆ (MH ⁺): 467.2923. Found : 467.2880; m.p. 190-192°C
92	2-(pyrrolidin-1-yl)ethoxy	t-butyl	H	121+29	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₃₃ N ₅ O (MH ⁺): 468.2763. Found : 468.2729; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 10.02 (1H, brs), 8.63 (1H, d), 8.53 (1H, d), 7.94 (2H, d), 7.91 (1H, s), 7.53-7.48 (2H, m), 7.43 (1H, d), 7.12-7.06 (1H, m), 6.96 (2H, d), 4.18 (2H, brt), 2.95 (2H, brt), 2.68 (4H, brs), 1.82 (4H, brs), 1.45 (9H, s).
93	4-ethyl-piperazin-1-yl	t-butyl	methyl	120+28	TOF MS ES ⁺ exact mass calculated for C ₃₀ H ₃₆ N ₆ (MH ⁺): 481.3080. Found : 481.3092; m.p. 210°C
94	methanesulfonyl	i-propyl	H	123	TOF MS ES ⁺ exact mass calculated for C ₂₃ H ₂₂ N ₄ O ₂ S (MH ⁺): 419.1542. Found : 419.1543; m.p. 134°C
95	methane-sulfonyl	i-propyl	methyl	122	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₄ N ₄ O ₂ S (MH ⁺): 433.1698. Found : 433.1654; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.62 (1H, d), 8.14 (2H, d), 8.09 (1H, s), 7.95 (2H, d), 7.52 (1H, d), 7.45 (1H, t), 7.31 (1H, d), 6.98 (1H, d), 3.16-3.04 (1H, m), 3.02 (3H, s), 2.41 (3H, s), 1.29 (6H, d).
96	(tetrahydropyr an-4-yl)amino-carbonyl	i-propyl	methyl	122+33	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₃₁ N ₅ O ₂ (MH ⁺): 482.2556. Found : 482.2509; m.p. 233°C

Ex.	R ¹	R ⁴	R ²	From Int.	Physical data
97	morpholin-4-yl	i-propyl	methyl	122+27	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₉ N ₅ O (MH ⁺): 440.2450. Found : 440.2419; m.p. 160°C (becomes gummy); ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 10.52 (1H, brs), 8.58 (1H, d), 7.94 (2H, d), 7.90 (1H, s), 7.45-7.30(3H, m), 7.00-6.87 (3H, m), 6.80 (2H, d), 3.83 (4H, brt), 3.20 (4H, brt), 3.17-3.06 (1H, m), 2.47 (3H, s), 1.35 (6H, d).
98	morpholin-4-yl	methyl	methyl	124+27	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ O (MH ⁺): 412.2137. Found : 412.2155; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.65 (1H, d), 8.03 (1H, s), 7.97 (2H, d), 7.55-7.40(3H, m), 7.04(1H, d), 6.97 (2H, d), 3.89 (4H, brt), 3.26 (4H, brt), 2.59 (3H, s), 2.56 (3H, s), NH imidazole not seen
99	(morpholin-4-yl)carbonyl	methyl	methyl	124+35	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₂ (MH ⁺): 440.2086. Found : 440.2144; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.72 (1H, d), 8.14 (1H, s), 8.09 (2H, d), 7.63-7.41(5H, m), 7.08(1H, d), 3.94-3.62 (8H, m), 2.62 (3H, s), 2.60 (3H, s), NH imidazole not seen.
100	morpholin-4-yl	i-propyl	H	123+27	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₇ N ₅ O (M+1) ⁺ : 425.2294. Found : 425.2295; m.p. 160°C (becomes gummy); ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.57 (1H, d), 8.47 (1H, d), 7.92 (1H, s), 7.87(2H, d), 7.49 (2H, brd), 7.36 (1H, d), 7.15-7.02 (1H, m), 6.90 (2H, d), 3.80 (4H, brt), 3.16 (4H, brt), 3.14-3.03 (1H, m), 1.34 (6H, d), NH imidazole not seen.


Example 101 : (4-{4-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-pyridin-2-yl}-benzyl)-dimethyl-amine



- 5 To a solution of intermediate 125 (0.8g, 2.02mmol) in CH₂Cl₂ (50ml) were added dimethylamine (2M solution in MeOH, 1.1ml, 2.22mmol) and sodium triacetoxymethylborohydride (0.856g, 4.04mmol) and the mixture was stirred at room

temperature for 3 hours. The reaction mixture was poured into a saturated solution of NaHCO₃ and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The title compound was obtained, after chromatography on silica gel (CH₂Cl₂/MeOH 98:2 then 85:15) and recrystallisation from EtOAc, as a white solid (0.109g, 12.6%); m.p. 187°C; TOF MS ES⁺ exact mass calculated for C₂₇H₃₁N₅:426.2657(MH⁺). Found : 426.2680(MH⁺).

The following compounds of formula (IDg) were prepared by methods analogous to that described for Example 101 using the starting materials indicated (see Table 19).




(IDg)

Table 19


Ex.	R ¹	R ⁴	From Int:	Physical data
102	morpholin-4-yl	t-butyl	125	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₃₃ N ₅ O (MH ⁺):468.2763. Found : 468.2764; ¹ H NMR (300 MHz; CDCl ₃ , ppm) δ: 8.77 (1H, d), 8.13 (1H, s), 8.05 (2H, d), 7.65-7.41(5H, m), 7.09(1H, d), 3.88-3.78 (4H, m), 3.69-3.62 (2H, m), 2.64 (3H, s), 2.60-2.54 (4H, m), 1.56 (9H, s), NH imidazole not seen.
103	pyrrolidin-1-yl	t-butyl	125	TOF MS ES ⁺ exact mass calculated for C ₂₉ H ₃₃ N ₅ (MH ⁺): 452.2814. Found : 452.2814; m.p. 148°C
104	morpholin-4-yl	i-propyl	127	TOF MS ES ⁺ exact mass calculated for C ₂₈ H ₃₁ N ₅ O (MH ⁺):454.2607. Found : 454.2574; m.p. 141°C
105	dimethylamino	i-propyl	127	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₉ N ₅ (MH ⁺): 412.2501. Found : 412.2523; m.p. 135°C

Example 106 : 4-(2-tert-Butyl-5-(6-methyl)-pyridin-2-yl)-1H-imidazol-4-yl)-2-[4-(1-methyl-1H-imidazol-4-yl)methoxy]-phenyl]-pyridine



To a solution of intermediate 126 (0.49g, 1.27mmol) in DMF (20ml) was added portionwise sodium hydride (60% in mineral oil, 0.152g, 3.81mmol) and the mixture was stirred at room temperature for 10 minutes. Intermediate 22 (0.3g, 1.8mmol) was then added and the mixture was stirred for 18 hours at room temperature and then poured into water. After extraction with EtOAc, the organic phase was washed with a solution of NaOH (1N) and water, dried over Na₂SO₄ and concentrated under reduced pressure. After precipitation with pentane, the title compound was obtained as an off-white solid (0.305g, 50%), gummy at 128°C; ¹H NMR (300 MHz; CDCl₃) δ: 8.51 (1H, d), 7.87 (1H, s), 7.82 (2H, d), 7.40 (1H, d), 7.40-7.28 (3H, m), 7.22 (1H, d), 6.96 (1H, d), 6.89 (1H, d), 6.85 (1H, s), 4.97 (2H, s), 3.56 (3H, s), 2.36 (3H, s), 1.32 (9H, s); TOF MS ES⁺ exact mass calculated for C₂₉H₃₀N₅O : 479.2559(MH⁺). Found 479.2549(MH⁺).


Example 107: 2-[4-[4-(2-tert-Butyl-5-{6-methyl}-pyridin-2-yl)-1H-imidazol-4-yl]-pyridin-2-yl]-phenoxy}-acetamide



Intermediate 126 (0.5g, 1.3mmol) and 2-bromoacetamide (0.197g, 1.43mmol) were reacted as described for example 106 to afford the title compound as a white solid (0.347g, 60.45%); m.p. 210°C; TOF MS ES⁺ exact mass calculated for C₂₆H₂₇N₅O₂ : 442.2243 (MH⁺). Found: 442.2221 (MH⁺).


Example 108: 4-(2-tert-Butyl-5-{6-methyl}-pyridin-2-yl)-1H-imidazol-4-yl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridine

100



Intermediate 126 (0.4g , 1.04mmol) and 1-(2-chloroethyl)pyrrolidine hydrochloride (0.354g, 2.08mmol) were reacted as described for example 106 to afford the title compound as an off-white solid (0.12g, 24%); m.p. 168°C; TOF MS ES⁺ exact mass
 5 calculated for C₃₀H₃₅N₅O : 482.2920(MH⁺). Found :482.2931 (MH⁺).


Example 109 : 4-(2-tert-Butyl-5-pyridin-2-yl-1H-imidazol-4-yl)-2-[4-(1-methyl-1H-imidazol-4-ylmethoxy)-phenyl]-pyridine



10 To a solution of example 83 (0.26g , 0.67mmol) in CH₂Cl₂ (40ml) was added boron tribromide (2.1ml, 2.1mmol, 3.2eq, solution 1M in CH₂Cl₂). The mixture was stirred at room temperature overnight. The reaction mixture was evaporated and neutralised with NaOH (1N), the resulting mixture was warmed up to 60°C and stirred for 1 hour. After cooling to room temperature, the mixture was extracted with CH₂Cl₂. The
 15 aqueous phase was acidified with HCl (1N) and extracted with CH₂Cl₂. The organic phase was washed with NaHCO₃, dried over Na₂SO₄, and concentrated under reduced pressure to give 4-(4-{2-tert-Butyl-5-pyridin-2-yl-1H-imidazol-4-yl}-pyridin-2-yl)-phenol which was used without purification in the next step. A solution of 4-(4-{2-tert-Butyl-5-pyridin-2-yl-1H-imidazol-4-yl}-pyridin-2-yl)-phenol (0.14g, 0.37mmol) in
 20 acetone K₂CO₃ (0.156g, 1.1mmol) and intermediate 22 (0.094g, 0.56mmol) were heated at reflux for 2 days. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was poured into water and extracted with CH₂Cl₂. The organic phase was washed with water, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by
 25 chromatography on silica gel (toluene/ isopropylamine 90:10) to afford the title

compound as a yellow solid (0.04g, 23.3%); m.p. 156°C; TOF MS ES⁺ exact mass calculated for C₂₈H₂₈N₆O : 465.2403 (MH⁺). Found: 465.2395 (MH⁺).


Example 110: 4-{2-Phenyl-5-[6-methyl]-pyridin-2-yl-1H-imidazol-4-yl}-2-(4-methanesulfonyl-phenyl)-pyridine



Intermediate 118 (6.5g, 20.3mmol) and benzaldehyde (4.3ml, 40.6mmol) were reacted as described for intermediate 119 to afford 2-phenyl-4-(pyridin-2-yl)-5-(2-bromo-pyridin-4-yl)-imidazole (4.5g) which was used in the next step without purification. 2-Phenyl-4-(pyridin-2-yl)-5-(2-bromo-pyridin-4-yl)-imidazole (0.6g, 1.53mmol) and 4-(methanesulfonyl)phenyl boronic acid (0.338g, 1.69mmol) were reacted as described for example 81 to afford the title compound as a yellow powder (0.14g, 19.63%); ¹H NMR (300 MHz; CDCl₃) δ: 8.67 (1H, d), 8.13-8.12 (2H, m), 7.96 (2H, d), 7.92 (1H, s), 7.68-7.26(8H, m), 7.02 (1H, d), 3.02 (3H, s), 2.54 (3H, s); TOF MS ES⁺ exact mass calculated for C₂₇H₂₂N₄O₂S: 467.1542 (MH⁺). Found : 467.1513 (MH⁺).

Aminothiazole Examples

Example 111: 5-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-yl]-4-(pyridin-2-yl)-1,3-thiazol-2-amine



To a solution of intermediate 45 (0.4 g, 1.11 mmol) in CH₂Cl₂ (20 ml) was added polymer-supported pyridinium perbromide (0.62g, 1eq, 1.11 mmol) and the suspension shaken for 50 min. The resin was removed by filtration, with the filtrate being added directly to thiourea (0.25 g, 3 eq, 3.33 mmol) and the resin washed several times with ethanol. The filtrate was heated at reflux overnight, allowed to cool

and concentrated. The residue was basified with aqueous NaOH and extracted with CH_2Cl_2 . The organic phase was washed with water, dried over Na_2SO_4 , and concentrated under reduced pressure. After chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 95:5 then 90:10) and crystallisation from ethyl acetate, the title compound was obtained as cream crystals (108 mg, 23.35%); m.p. 246°C; [APCI MS] m/z 416 (MH^+).

The following compounds of formula (IEf) were prepared by methods analogous to that described for Example 111 using the starting materials indicated (see Table 20).





Table 20

Ex.	R ¹	From Int.	Physical data
112	methanesulfonyl	46	TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₈ N ₄ O ₂ S ₂ (MH ⁺): 423.0949. Found: 423.0945; m.p. 236-238°C
113	4-ethylpiperazin-1-yl	47	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₈ N ₆ S (MH ⁺): 457.2174. Found : 457.2213; m.p. 230-232°C
114	morpholin-4-yl	48	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ OS (MH ⁺): 430.1701. Found : 430.1698; m.p. 250-252°C
115	(morpholin-4-yl)carbonyl	57	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₃ N ₅ O ₂ S (MH ⁺): 458.1651. Found : 458.1602; m.p. 158-160°C
116	(tetrahydropyran-4-yl)amino carbonyl	58	[APCI MS] m/z : 472 (MH ⁺); m.p. 230-232°C
117	(morpholin-4-yl)methyl	59	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ OS (MH ⁺): 443.1860. Found : 443.1800; m.p. 190-192°C
118	methoxy	51	[APCI MS] m/z : 375 (MH ⁺); m.p. 188-190°C
119	trifluoromethoxy	52	[APCI MS] m/z : 429 (MH ⁺); m.p. 222-224°C
120	aminocarbonyl methoxy	54	[APCI MS] m/z : 418 (MH ⁺); m.p. 152-154°C
121	2-(pyrrolidin-1-yl)ethoxy	53	[APCI MS] m/z : 458 (MH ⁺); m.p. 176-178°C

Ex.	R ¹	From Int.	Physical data
122	(1-methylimidazol-4-yl)methoxy	55	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₂ N ₆ OS (MH ⁺): 455.1654. Found : 455.1600; m.p. 226-228°C

The following compounds of formula (IEg) were prepared by methods analogous to that described for Example 111 using the starting materials indicated (see Table 21).



5

Table 21

Ex.	R ¹	R ²	From Int.	Physical data
123	(tetrahydropyran-4-yl)amino carbonyl	H	65	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₃ N ₅ O ₂ S (MH ⁺): 458.1651. Found : 458.1637; m.p. 268°C
124	morpholin-4-yl	H	66	TOF MS ES ⁺ exact mass calculated for C ₂₃ H ₂₁ N ₅ OS (MH ⁺): 416.1545. Found : 416.1504; m.p. 276°C
125	chloro	methyl	67	TOF MS ES ⁺ exact mass calculated for C ₂₀ H ₁₅ ClN ₄ S (MH ⁺): 379.0784. Found : 379.0772; m.p. 222°C
126	trifluoromethoxy	methyl	68	TOF MS ES ⁺ exact mass calculated for C ₂₁ H ₁₅ F ₃ N ₄ OS (MH ⁺): 429.0997. Found: 429.0958; m.p. 232°C
127	ethanesulfonyl	methyl	61	TOF MS ES ⁺ exact mass calculated for C ₂₂ H ₂₀ N ₄ O ₂ S ₂ (MH ⁺): 437.1106. Found: 437.1096; m.p. 219°C
128	(tetrahydropyran-4-yl)aminocarbonyl	methyl	71	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₂ S (MH ⁺): 472.1807. Found : 472.1815; m.p. 283°C
129	(morpholin-4-yl)carbonyl	methyl	69	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₃ N ₅ O ₂ S (MH ⁺): 458.1651. Found : 458.1610; m.p. 246°C
130	(4-ethylpiperazin-1-yl)carbonyl	methyl	70	TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₈ N ₆ OS (MH ⁺): 485.2123. Found : 485.2128; m.p. 224°C
131	(morpholin-4-yl)methyl	methyl	77	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ OS (MH ⁺): 444.1858. Found : 444.1862; m.p. 236°C
132	morpholin-4-yl	Methyl	72	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ OS (MH ⁺): 430.1701. Found : 430.1648; m.p. 246°C

Ex.	R ¹	R ²	From Int.	Physical data
133	2-(pyrrolidin-1-yl)ethoxy	methyl	73	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₇ N ₅ OS (MH ⁺): 458.2014. Found : 458.1963; m.p. 150°C
134	aminocarbonylmethoxy	methyl	74	TOF MS ES ⁺ exact mass calculated for C ₂₂ H ₁₉ N ₅ O ₂ S (MH ⁺): 418.1338. Found : 418.1289; m.p. 191°C
135	(morpholin-4-yl)carbonylmethoxy	methyl	75	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₃ S (MH ⁺): 488.1756. Found : 488.1700; m.p. 172°C
136	(pyrrolidin-1-yl)methyl	methyl	78	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ S (MH ⁺): 428.1909. Found : 428.1861; m.p. 200°C
137	(dimethylamino)methyl	methyl	79	TOF MS ES ⁺ exact mass calculated for C ₂₃ H ₂₃ N ₅ S (MH ⁺): 402.1752. Found : 402.1707; m.p. 210°C

Examples 138 to 140

Step 1: Intermediate 128 supported on resin (1g) was weighed out into a peptide vessel. Then 4-formylphenylboronic acid (870mg, 5.8mmol, 10eq), Pd(PPh₃)₄ (134 mg, 0.16mmol, 0.2eq), and sodium carbonate (615mg, 5.8mmol, 2M) were added and suspended in toluene/EtOH (8:2, 20mL). The reaction vessel was purged with argon for 5 min, and the mixture was stirred at 90°C for 16h. The resin was washed with DMF (3x10mL), water (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL).

Step 2: The product from step 1 was placed into a peptide vessel with a solution of NHR⁵R⁶ (5.8mmol, 10eq) in trimethylorthoformate (5.4mL). Then a solution of sodium cyanoborohydride (0.2M) in THF (5.4mL) with acetic acid (110μL) was added. The reaction vessel was purged with argon for 5 min and the mixture was stirred at 60°C for 16h. The resin was washed with DMF (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL). The resin was treated with a solution of 20% TFA in CH₂Cl₂ and the solvent was removed under reduced pressure. Purification of the residue by HPLC chromatography (water/ acetonitrile gradient) gave the products of formula (IEh) shown in Table 22.





Table 22

Ex	R ⁵	R ⁶	Physical data
138	H	isopropyl	[APCI MS] m/z 402 MH+
139		-(CH ₂) ₄ -	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ S (MH ⁺): 414.1752. Found : 414.1766.
140	H	cyclobutyl	TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ S (MH ⁺): 414.1752. Found : 414.1749.

Examples 141 to 144



- Step 1: Intermediate 128 or intermediate 129 supported on resin (1g) were weighed out into a peptide vessel. Then 4-hydroxyphenylboronic acid (800mg, 5.8mmol, 10eq), Pd(PPh₃)₄ (134 mg, 0.16mmol, 0.2eq), and sodium carbonate (615mg, 5.8mmol, 2M) were added and suspended in toluene/EtOH (8:2, 20mL). The reaction vessel was purged with argon for 5 min, and the mixture was stirred at 90°C for 16h. The resin was washed with DMF (3x10mL), water (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL).
- Step 2: The product from step 1 was placed into a peptide vessel with a solution of R-Cl (5.8mmol, 10eq) in DMSO (10mL). Then a solution of potassium carbonate (802mg, 5.8mmol, 10eq) in DMSO (5mL) was added. The reaction vessel was purged with argon for 5 min and the mixture was stirred at 90°C for 16h. The resin was washed with DMF (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL). The resin was treated with a solution of 20% TFA in CH₂Cl₂ and the solvent was removed under reduced pressure. Purification of the residue by HPLC chromatography (water/acetonitrile gradient) gave the products of formula (IEj) shown in Table 23.



(IEj)

Table 23

Ex	R	R ²	From intermediate supported on resin	Physical data
141		methyl	55	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₁ N ₅ O ₂ S (MH ⁺): 456.1494. Found: 456.1457.
142		H	54	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₁ N ₅ O ₂ S (MH ⁺): 456.1494. Found: 456.1545.

Ex	R	R ²	From intermediate supported on resin	Physical data
143		methyl	55	TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₃ S (MH ⁺): 488.1756. Found : 488.1792.
144		H	54	TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₃ N ₅ O ₃ S (MH ⁺): 474.1600. Found : 474.1552.


Examples 145 to 156

Step 1: Intermediate 129 supported on resin (1g) was weighed out into a peptide vessel. Then 4-methoxycarbonylphenylboronic acid (1.05g, 5.8mmol, 10eq),

- 5 Pd(PPh₃)₄ (0.134 g, 0.16mmol, 0.2eq), and a aqueous solution of sodium carbonate (0.615g, 5.8mmol, 2M) were added and suspended in toluene/EtOH (8:2, 20mL). The reaction vessel was purged with argon for 5 min, and the mixture was stirred at 90°C for 16h. The resin was washed with DMF (3x10mL), water (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL). Then resin was added to a sodium hydroxide solution (2M) in
- 10 dioxane (10mL). The reaction mixture was stirred at 50°C for 16h. The resin was washed with DMF (3x10mL), EtOH (3x10mL) and CH₂Cl₂ (3x10mL).













- Step 2: The product from step 1 was placed into a peptide vessel with a solution of NHR⁵R⁶ (5.8mmol, 10eq) in DMF (5mL). Then a solution of HOBT (1.18g, 8.7mmol, 15eq) and EDCI (1.36mL, 8.7mmol, 15eq) in DMF (5mL) was added. The reaction
- 15 vessel was purged with argon for 5 min and the mixture was stirred at 70°C for 16h. The resin was washed with DMF (3x10mL), EtOH (3x10mL), CH₂Cl₂ (3x10mL). The resin was treated with a solution of 20% TFA in CH₂Cl₂ and the solvent was removed under reduced pressure. Purification of the residue by HPLC chromatography (water/ acetonitrile gradient) gave the products of formula (IEk) shown in Table 24.

20



(IEk)

Table 24

Ex	R ⁶ R ⁵ NCO-	Physical data
145		TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₈ N ₆ OS (MH ⁺): 485.2123. Found :485.2123.
146		TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₃₀ N ₆ OS (MH ⁺): 487.2280. Found :487.2267.
147		TOF MS ES ⁺ exact mass calculated for C ₂₈ H ₃₀ N ₆ OS (MH ⁺): 499.2280. Found :499.2277.
148		TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₈ N ₆ OS (MH ⁺): 485.2123. Found :485.2094.
149		TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ O ₂ S (MH ⁺): 460.1807. Found :460.1810.
150		TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₃₀ N ₆ OS (MH ⁺): 487.2280. Found :487.2260.
151		TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₅ N ₅ O ₂ S (MH ⁺): 460.1807. Found :460.1799.
152		TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₅ N ₅ O ₂ S (MH ⁺): 472.1807. Found :472.1798.
153		TOF MS ES ⁺ exact mass calculated for C ₂₄ H ₂₃ N ₅ O ₂ S (MH ⁺): 466.1651. Found :466.1633.
154		TOF MS ES ⁺ exact mass calculated for C ₂₅ H ₂₂ N ₆ OS (MH ⁺): 455.1654. Found :455.1626.
155		TOF MS ES ⁺ exact mass calculated for C ₂₆ H ₂₉ N ₅ OS (MH ⁺): 484.2171. Found :484.2133.
156		TOF MS ES ⁺ exact mass calculated for C ₂₇ H ₂₇ N ₅ OS (MH ⁺): 470.2014. Found :470.1964.

Biology

The biological activity of the compounds of the invention may be assessed using the following assays:

Assay 1 (Cellular transcriptional assay)

The potential for compounds of the invention to inhibit TGF- β signalling may be demonstrated, for example, using the following in vitro assay.

- 5 The assay was performed in HepG2 cells stably transfected with the PAI-1 promoter (known to be a strong TGF- β responsive promoter) linked to a luciferase (firefly) reporter gene. The compounds were selected on their ability to inhibit luciferase activity in cells exposed to TGF- β . In addition, cells were transfected with a second luciferase (Renilla) gene which was not driven by a TGF- β responsive promoter and
- 10 was used as a toxicity control.

96 well microplates were seeded, using a multidrop apparatus, with the stably transfected cell line at a concentration of 35000 cells per well in 200 μ l of serum-containing medium. These plates were placed in a cell incubator.

- 18 to 24 hours later (Day 2), cell-incubation procedure was launched. Cells were
- 15 incubated with TGF- β and a candidate compound at concentrations in the range 50 nM to 10 μ M (final concentration of DMSO 1%). The final concentration of TGF- β (rhTGF β -1) used in the test was 1 ng/mL. Cells were incubated with a candidate compound 15-30 mins prior to the addition of TGF- β . The final volume of the test reaction was 150 μ l. Each well contained only one candidate compound and its
- 20 effect on the PAI-1 promoter was monitored.

- Columns 11 and 12 were employed as controls. Column 11 contained 8 wells in which the cells were incubated in the presence of TGF- β , without a candidate compound. Column 11 was used to determine the 'reference TGF- β induced firefly luciferase value' against which values measured in the test wells (to quantify
- 25 inhibitory activity) were compared. In wells A12 to D12, cells were grown in medium without TGF- β . The firefly luciferase values obtained from these positions are representative of the 'basal firefly luciferase activity'. In wells E12 to H12, cells were incubated in the presence of TGF- β and 500 μ M CPO (Cyclopentenone, Sigma), a cell toxic compound. The toxicity was revealed by decreased firefly and renilla
- 30 luciferase activities (around 50 % of those obtained in column 11).

- 12 to 18 hours later (day 3), the luciferase quantification procedure was launched. The following reactions were performed using reagents obtained from a Dual Luciferase Assay Kit (Promega). Cells were washed and lysed with the addition of 10 μ l of passive lysis buffer (Promega). Following agitation (15 to 30 mins), luciferase
- 35 activities of the plates were read in a dual-injector luminometer (BMG lumistar). For

this purpose, 50 μ l of luciferase assay reagent and 50 μ l of 'Stop & Glo' buffer were injected sequentially to quantify the activities of both luciferases. Data obtained from the measurements were processed and analysed using suitable software. The mean Luciferase activity value obtained in wells A11 to H11 (Column 11, TGF- β only) was considered to represent 100% and values obtained in wells A12 to D12 (cells in medium alone) gave a basal level (0%). For each of the compounds tested, a concentration response curve was constructed from which an IC₅₀ value was determined graphically.

10 Assay 2 (Alk5 Fluorescence Polarization Assay)

Kinase inhibitor compounds conjugated to fluorophores, can be used as fluorescent ligands to monitor ATP competitive binding of other compounds to a given kinase. The increase in depolarization of plane polarized light, caused by release of the bound ligand into solution, is measured as a polarization/anisotropy value. This protocol details the use of a rhodamine green-labelled ligand for assays using recombinant GST-ALK5 (residues 198-503).

Assay buffer components: 62.5 mM Hepes pH 7.5 (Sigma H-4034), 1 mM DTT (Sigma D-0632), 12.5 mM MgCl₂ (Sigma M-9272), 1.25 mM CHAPS (Sigma C-3023).

Protocol: Solid compound stocks were dissolved in 100% DMSO to a concentration of 1 mM and transferred into column 1, rows A-H of a 96-well, U bottom, polypropylene plate (Costar #3365) to make a compound plate. The compounds were serially diluted (3-fold in 100% DMSO) across the plate to column 11 to yield 11 concentrations for each test compound. Column 12 contained only DMSO. A Rapidplate™-96 was used to transfer 1 μ l of sample from each well into a 96-well, black, U-bottom, non-treated plate (Costar #3792) to create an assay plate.

ALK5 was added to assay buffer containing the above components and 1 nM of the rhodamine green-labelled ligand so that the final ALK5 concentration was 10 nM based on active site titration of the enzyme. The enzyme/ligand reagent (39 μ l) was added to each well of the previously prepared assay plates. A control compound (1 μ l) was added to column 12, rows E-H for the low control values. The plates were read immediately on a LJL Acquest fluorescence reader (Molecular Devices, serial number AQ1048) with excitation, emission, and dichroic filters of 485nm, 530 nm, and 505 nm, respectively. The fluorescence polarization for each well was

calculated by the Acquest reader and then imported into curve fitting software for construction of concentration response curves. The normalized response was determined relative to the high controls (1 μ l DMSO in column 12, rows A-D) and the low controls (1 μ l of control compound in column 12, rows E-H). An IC_{50} value was then calculated for each compound


Using the above assays all Examples of the invention show ALK5 receptor modulator activity (having IC_{50} values in the range of 0.4 to 275nM) and TGF- β cellular activity (having IC_{50} values in the range of 0.001 to 10 μ M).

4-{4-[4-(2-*tert*-Butyl-5-{6-methyl}-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 86) showed an ALK5 receptor modulator activity of 34 nM and TGF- β cellular activity of 183 nM.

N-(tetrahydropyran-4-yl)-4-(4-{2-isopropyl-5-[6-methyl-pyridin-2-yl]-1*H*-imidazol-4-yl}-pyridin-2-yl)-benzamide (Example 96) showed an ALK5 receptor modulator activity of 25 nM and TGF- β cellular activity of <14 nM.

Claims

- 1 A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:



(I)

5 wherein

A is furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazole, isoxazole, oxazoline, oxazolidine, thiazole, isothiazole, thiadiazole, benzofuran, indole, isoindole, indazole, imidazopyridine, quinazoline, quinoline, isoquinoline, pyrazole or triazole;

10

X is N or CH;

R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro C₁₋₆alkyl, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -CO(CH₂)_nNR⁵R⁶, -SO₂R⁷, -SO₂NR⁵R⁶, -NR⁵SO₂R⁷, -NR⁵COR⁷, -O(CH₂)_nCONR⁵R⁶, -NR⁵CO(CH₂)_nNR⁵R⁶ or -C(O)R⁷;

15

R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, phenyl, C₁₋₆alkyl or -NR⁵R⁶;

20

where

R⁵ and R⁶ are independently selected from hydrogen; Het; C₃₋₆cycloalkyl optionally substituted by C₁₋₆alkyl; or by C₁₋₆alkyl optionally substituted by Het, alkoxy, cyano or -NR^aR^b (where R^a and R^b which may be the same or different are hydrogen or C₁₋₆alkyl, or R^a and R^b together with the nitrogen atom to which they are attached may form a 4,5 or 6-membered saturated ring); or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be

25

further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-\text{CF}_3$, hydroxy, $-\text{OCF}_3$, C_{1-6} alkyl and C_{1-6} alkoxy;

R^7 is selected from hydrogen and C_{1-6} alkyl;

5 Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C_{1-6} alkyl; and

n is 1-4;

10 with the provisos that :

a) when A is thiazole (wherein the thiazole sulfur is on the same side as the 4-pyridyl moiety); X is N; R^1 is hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo, cyano, perfluoro C_{1-6} alkyl or perfluoro C_{1-6} alkoxy; R^2 is hydrogen, C_{1-6} alkyl, halo, cyano or perfluoro C_{1-6} alkyl; and R^3 is hydrogen or halo; 15 then R^4 is not NH_2 ; and

b) when X is N, A is pyrazole (where the ring containing X is attached to the pyrazole ring at carbon atom next to a pyrazole ring nitrogen), R^2 is hydrogen then R^3 is not hydrogen.

20 2 A compound according to any preceding claim wherein A is imidazole optionally substituted by one R^4 substituent.

3 A compound according to any preceding claim wherein X is N.

25 4 A compound according to any preceding claim wherein R^1 is C_{1-6} alkyl, C_{1-6} alkoxy, halo, cyano, perfluoro C_{1-6} alkoxy, $-\text{NR}^5\text{R}^6$, $-(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{O}(\text{CH}_2)_n\text{OR}^7$, $-\text{O}(\text{CH}_2)_n\text{-Het}$, $-\text{O}(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{CONR}^5\text{R}^6$, $-\text{SO}_2\text{R}^7$, $-\text{NR}^5\text{SO}_2\text{R}^7$, $-\text{NR}^5\text{COR}^7$, $-\text{O}(\text{CH}_2)_n\text{CONR}^5\text{R}^6$, $-\text{NR}^5\text{CO}(\text{CH}_2)_n\text{NR}^5\text{R}^6$ or $-\text{C}(\text{O})\text{R}^7$.

30 5 A compound according to any preceding claim wherein R^2 is hydrogen, C_{1-6} alkyl or fluoro.

6 A compound according to any preceding claim wherein R^3 is hydrogen.

35 7 A compound according to any preceding claim wherein R^4 is hydrogen, phenyl, C_{1-6} alkyl or halo.

8 A compound according to any preceding claim wherein R^5 and R^6 are
independently selected from hydrogen; Het; C_{3-6} cycloalkyl optionally
substituted by C_{1-6} alkyl; or by C_{1-6} alkyl optionally substituted by Het, alkoxy,
5 cyano or $-NR^aR^b$ (where R^a and R^b which may be the same or different are
hydrogen or C_{1-6} alkyl, or R^a and R^b together with the nitrogen atom to which
they are attached may form a 4, 5 or 6-membered saturated ring); or R^5 and
 R^6 together with the atom to which they are attached form a morpholine,
piperidine, pyrrolidine or piperazine ring, each of which may be substituted by
10 halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl or
 C_{1-4} alkoxy.

9 A compound according to claim 1 wherein
A is imidazole;
15 X is N;
 R^1 is C_{1-6} alkyl, C_{1-6} alkoxy, halo, cyano, perfluoro C_{1-6} alkoxy, $-NR^5R^6$,
 $-(CH_2)_nNR^5R^6$, $-(CH_2)_nOR^7$, $-O(CH_2)_n$ -Het, $-O(CH_2)_nNR^5R^6$, $-CONR^5R^6$,
 $-SO_2R^7$, $-NR^5SO_2R^7$, $-R^5COR^7$, $-O(CH_2)_nCONR^5R^6$,
 $-NR^5CO(CH_2)_nNR^5R^6$ or $-C(O)R^7$;
20 R^2 is hydrogen, C_{1-6} alkyl or fluoro;
 R^3 is hydrogen or halo;
 R^4 is hydrogen, phenyl, C_{1-6} alkyl or halo;
 R^5 and R^6 are independently selected from hydrogen, Het or C_{1-6} alkyl; or R^5
and R^6 together with the atom to which they are attached form a
25 morpholine, piperidine, pyrrolidine or piperazine ring, each of which
may be substituted by halo (such as fluoro, chloro, bromo), cyano,
 $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl or C_{1-4} alkoxy;
 R^7 is selected from hydrogen and C_{1-6} alkyl;
Het is a 5 or 6-membered C-linked heterocyclyl group which may be
30 saturated, unsaturated or aromatic, which may contain one or more
heteroatoms selected from N, S or O and which may be substituted by
 C_{1-6} alkyl; and
n is 1-4.

35 10 A compound according to claim 1 wherein the compound is selected from the
list:

4-{2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl}-2-(4-methanesulfonyl-phenyl)-pyridine (Example 84);
4-{4-[4-(2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 86);
5 N-(tetrahydropyran-4-yl)-4-(4-[2-isopropyl-5-[6-methyl]-pyridin-2-yl]-1*H*-imidazol-4-yl)-pyridin-2-yl)-benzamide (Example 96);
4-{4-[4-(2-isopropyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl}-morpholine (Example 97);
4-(4-[4-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl]-benzyl)- dimethyl-amine (Example 105);
10 4-(4-[4-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl]-benzyl)-morpholine (Example 104);
N-(tetrahydropyran-4-yl)-4-(4-[2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl]-1*H*-imidazol-4-yl)-pyridin-2-yl)-benzamide (Example 81);
15 (4-[4-[2-*tert*-Butyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-pyridin-2-yl]-benzyl)-pyrrolidine (Example 103);
4-(2-*tert*-Butyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyridine (Example 108); and
4-[4-[4-(2-methyl-5-[6-methyl]-pyridin-2-yl-1*H*-imidazol-4-yl)-pyridin-2-yl]-phenyl]-morpholine (Example 98);
20 and pharmaceutically acceptable salts, solvates and derivatives thereof.

- 11 A pharmaceutical composition comprising a compound defined in any preceding claim and a pharmaceutically acceptable carrier or diluent.
- 25 12 The use of a compound defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prophylaxis of a disorder mediated by the ALK5 receptor in mammals.
- 30 13 The use according to claim 12 wherein the disorder is selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease
35 wherein fibrosis is a major component, including, but not limited to lung fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV),

hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis, mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis, endometriosis, keloids and restenosis.

- 5 14 The use according to claim 13 wherein the disorder is kidney fibrosis.
- 15 A compound defined in any one of claims 1 to 10 for use as a medicament.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08496

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/14 C07D401/14 C07D407/14 C07D471/04 A61K31/4439
A61K31/444 A61P1/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 066462 A (GELLIBERT FRANCOISE JEANNE ;GLAXO GROUP LTD (GB); MATHEWS NEIL (GB) 29 August 2002 (2002-08-29) claims ---	1-15
P,A	WO 02 062753 A (GELLIBERT FRANCOISE JEANNE ;GLAXO GROUP LTD (GB)) 15 August 2002 (2002-08-15) the whole document ---	1-15
A	WO 02 40476 A (GASTER LARAMIE MARY ;HEIGHTMAN THOMAS DANIEL (GB); PAYNE ANDREW HE) 23 May 2002 (2002-05-23) the whole document --- -/--	1-15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

12 November 2003

Date of mailing of the international search report

25/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schmid, J-C

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/08496

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02 40468 A (SMITHKLINE BEECHAM CORP ;BENDER PAUL E (US); BURGESS JOELLE L (US)) 23 May 2002 (2002-05-23) the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08496

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02066462	A	29-08-2002	WO 02066462 A1 EP 1355903 A1	29-08-2002 29-10-2003
WO 02062753	A	15-08-2002	WO 02062753 A1 EP 1355870 A1	15-08-2002 29-10-2003
WO 0240476	A	23-05-2002	AU 1416302 A EP 1335916 A1 WO 0240476 A1	27-05-2002 20-08-2003 23-05-2002
WO 0240468	A	23-05-2002	AU 2573002 A EP 1349851 A1 WO 0240468 A1	27-05-2002 08-10-2003 23-05-2002